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To my family, for being there for me 
"Nothing in life is to be feared, it is only to be understood. Now is the time to 
understand more, so that we may fear less." ― Marie Curie 
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ABSTRACT 
Background: According to the National Diabetes Register (NDR) report (2016), 21.2% of 
adults with type 1 diabetes (T1D) achieve glycemic targets measured with HbA1c (52 mmol / 
mol) and 20.1% of patients have very poor glycemic control (HbA1c> 70 mmol / mol). In recent 
years, a positive trend in improving HbA1c has been observed; despite it, there is a great need 
to understand how diabetes-care can be improved. Thus, the following questions were 
formulated: To what extent are international guidelines for visits with HbA1c controls in T1D 
followed? (Study I) Which of the two most commonly used CGM sensors is most accurate in 
estimating blood glucose levels and which CGM system is most user-friendly? (Study II) Can 
some patient subgroups have greater effect on insulin pump treatment than others? (Study III) 
What is the excess risk of acute coronary events for persons with T1D compared to persons 
without T1D in Sweden, when modern guidelines have been implemented? How does this risk 
differ for people with T1D in relation to glycemic control and renal complications? (Study IV) 
 
Material and methods: To calculate the HbA1c yearly measurement rate, we included patients 
from 10 diabetes clinics in Sweden. Data were collected via the Diab-Base electronic record 
system (study I). Persons with T1D and insulin pump use for at least 5 years who had HbA1c 
measurement at the beginning and end of the period and patients with insulin injections were 
included from Dia-Base in study III. In an economically independent from manufacturers 
clinical trial on precision and treatment satisfaction with 2 different CGM (Dexcom G4 and 
Enlite) systems, ambulatory patients with T1D were included (study II). All patients arrived at 
three scheduled visits for blood sampling and filled in a questionnaire regarding treatment 
satisfaction. In a study of risk of myocardial infarction in persons with T1D compared to controls 
(study IV), we included patients registered in NDR (n = 33 886) and 5 randomly selected 
matched controls (n = 169 223). Through interaction with data from the National Board of Social 
Services, data were collected on cardiovascular disease, death date and causes of death. 
 
Results and conclusions: Persons with T1D, get fewer than 2 HbA1c controls per year on 
average in Sweden against recommended 4 controls per year. Patients with insulin injections 
receive fewer HbA1c controls and need extra focus (study I). We found that DexCom G4 had a 
higher precision and treatment satisfaction, which is likely to make adequate decisions on 
treatment (study II). We found no strong predictors for the greater effect of insulin pump on 
lowering HbA1c. The decrease was 2.5 mmol / mol at very high HbA1c compared with about 2 
mmol / mol on average. However, insulin pump treatment has a value since a certain decrease 
in HbA1c occurs (study III). Persons with T1D still had about 4 times the risk of cardiac 
 infarction than persons without diabetes in Sweden. The risk is significantly lower for people 
with good glycemic control and absence of renal complications. Continued focus on better 
methods for improving HbA1c, as well as primary and secondary prevention of coronary artery 
disease are essential for reducing the risk of coronary complications in T1D.  
Keywords: Diabetes, type 1, HbA1c, CGM, insulin pump, major coronary events 
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SAMMANFATTNING PÅ SVENSKA 
Bakgrund: Enligt rapporten från Nationella Diabetesregistret (NDR) (2016) är det enbart 21,2% 
av vuxna personer med typ 1 diabetes (T1D) som uppnår glykemiskt mål mätt med HbA1c (52 
mmol/mol) och 20,1% av patienterna har mycket dålig glykemisk kontroll 
(HbA1c>70mmol/mol). Trots att det under de senaste åren observerats en positiv trend, vad 
gäller förbättring av HbA1c, finns ett stort behov att förstå hur diabetesvården kan förbättras. 
Mot bakgrund av detta, formulerades följande frågor: I vilken utsträckning följs de 
internationella riktlinjerna för besök med HbA1c-kontroller vid typ 1 diabetes? (Studie I) Vilken 
av de två mest använda CGM-sensorerna är mest exakt i att skatta blodsockernivån och vilket 
CGM-system är mest användarvänligt för patienten? (Studie II) Kan vissa patientsubgrupper ha 
större effekt av insulinpumpbehandling än andra? (Studie III) Hur skiljer sig risken att drabbas 
av hjärtinfarkt för personer med typ 1 diabetes och övriga befolkningen i Sverige under 2000-
talet när moderna riktlinjer har implementerats? Hur skiljer sig denna risk för personer med typ 
1 diabetes beroende på glykemisk kontroll och njurkomplikationer? (Studie IV) 
Metoder: För att beräkna HbA1c mätningsfrekvensen inkluderade vi patienter från 10 
diabetesmottagningar i Sverige. Data insamlades via det elektroniska journalsystemet Diab-Base 
(studie I). Patienter med insulinpumpanvändning i minst 5 år och som hade HbA1c mätning i 
början och slutet av perioden och patienter med insulininjektioner inkluderades från Dia-Base 
till studie III. I en ekonomiskt oberoende klinisk prövning avseende precision och 
behandlingstillfredsställelse av 2 olika CGM-system (Dexcom G4 och Enlite) inkluderades 
ambulatoriska T1D patienter (studie II). Samtliga patienter använde samtidigt de två CGM-
systemen och kom på tre planerade återbesök för provtagning. Varje patient fyllde i en enkät 
avseende behandlingstillfredsställelse. Avseende studie om ökad risk för hjärtinfarkt vid T1D 
jämfört med kontroller så inkluderade vi patienter som var registrerade i NDR (n=33 886) och 
5 slumpmässigt utvalda matchade kontroller (n=169 223). Genom samkörning med data från 
socialstyrelsens patientregister, inhämtades data om hjärtkärlsjukdom, dödsdatum och 
dödsorsaker. 
Resultat och slutsatser: Hos personer med T1D sker inte ens 2 HbA1c-kontroller per år i 
genomsnitt i Sverige mot rekommenderade 4 kontroller per år. Patienter med insulininjektioner 
erhåller färre HbA1c-kontroller och behöver extra fokus (studie I). I en oberoende studie fann 
vi att DexCom G4 hade en högre precision och behandlingstillfredsställelse, vilket sannolikt är 
av betydelse för att göra adekvata beslut om behandling (studie II). Vi fann inga starka 
prediktorer för större effekt av insulinpump på att sänka HbA1c där sänkningen var 2,5 
mmol/mol vid mycket höga HbA1c jämfört med ca 2 mmol/mol i genomsnitt. 
Insulinpumpbehandling har dock ett värde då en viss sänkning i HbA1c sker och effekter finns 
enligt andra studier på livskvalité och hypoglykemier (studie III). Personer med T1D hade 
fortsatt ca 4 gånger högre risk för hjärtinfarkt än övriga befolkningen i Sverige. Överrisken är 
betydligt lägre för personer med god glykemisk kontroll och frånvaro av njursjukdom. Fortsatt 
fokus på bättre metoder för att förbättra HbA1c, minska rökning, öka fysisk aktivitet och 
behandla lipidnivåer och blodtrycksnivåer är essentiellt för att minska risken för hjärtinfarkter 
vid typ 1 diabetes. 
i 
LIST OF PAPERS  
This thesis is based on the following studies, referred to in the text by their 
Roman numerals. 
I. Matuleviciene V, Attvall S, Ekelund M, Clements M, 
Dahlqvist S, Fahlén M, Pivodic A, Haraldsson B, Lind M. A 
Retrospective Study in 5,989 Patients with Type 1 Diabetes 
in 10 Outpatient Diabetes Clinics in Sweden of the 
Frequency of Measuring HbA1c in Clinical Practice. J 
Diabetes Metab. 2014;5:377 
II. Matuleviciene V, Joseph JI, Andelin M, Hirsch IB, Attvall 
S, Pivodic A, Dahlqvist S, Klonoff D, Haraldsson B, Lind 
M. A Clinical Trial of the Accuracy and Treatment 
Experience of the Dexcom G4 Sensor (Dexcom G4 System) 
and Enlite Sensor (Guardian REAL-Time System) Tested 
Simultaneously in Ambulatory Patients with Type 1 
Diabetes. Diabetes Technol Ther. 2014;16(11):759-67. 
III. Clements M, Matuleviciene V, Attvall S, Ekelund M, 
Pivodic A, Dahlqvist S, Fahlen M, Haraldsson B, Lind M. 
Predicting the effectiveness of insulin pump therapy on 
glycemic control in clinical practice: A retrospective study 
of patients with type 1 diabetes from 10 outpatient diabetic 
clinics in Sweden over 5 years. Diabetes Technol Ther. 
2015;17(1):21-8. 
IV. Matuleviciene-Anängen, V., Rosengren, A., Svensson, A. 
M., Pivodic, A., Gudbjörnsdottir, S., Wedel, H., Kosiborod, 
M., Haraldsson, B., Lind, M. (2017). Glycaemic control and 
excess risk of major coronary events in persons with type 1 
diabetes. Heart 2017;103:1687-1695. 
  
ii 
CONTENT 
 
SAMMANFATTNING PÅ SVENSKA ..................................................................... 7 
LIST OF PAPERS ............................................................................................ I 
CONTENT .......................................................................................................... II 
ABBREVIATIONS ............................................................................................. IV 
FOREWORD ..................................................................................................... VI 
1 INTRODUCTION ........................................................................................... 1 
1.1 Rationale ............................................................................................... 1 
1.2 Type 1 diabetes, historical moments ..................................................... 4 
1.2.1 Insulin discovery ........................................................................... 6 
2 DIABETES CARE TODAY: HBA1C, CARDIOVASCULAR COMPLICATIONS AND 
TECHNICAL DEVICES ........................................................................................ 9 
2.1 HbA1c tests ........................................................................................... 9 
2.1.1 Conditions that may affect HbA1c levels .................................... 11 
2.1.2 Why glucose level matters? ......................................................... 11 
2.2 Cardiovascular complications ............................................................. 16 
2.3 Diabetes care today: technical implementation ................................... 22 
3 AIM ........................................................................................................... 28 
4 PATIENTS AND METHODS ......................................................................... 29 
4.1 Data source .......................................................................................... 34 
4.2 Procedures ........................................................................................... 36 
4.3 Statistical analysis ............................................................................... 39 
4.4 Ethical considerations ......................................................................... 42 
5 RESULTS ................................................................................................... 43 
5.1.1 Study I ......................................................................................... 43 
5.1.2 Study II ........................................................................................ 46 
5.1.3 Study III....................................................................................... 49 
5.1.4 Study IV ...................................................................................... 51 
6 DISCUSSION .............................................................................................. 53 
iii 
7 CONCLUSION ............................................................................................ 60 
8 FUTURE PERSPECTIVES ............................................................................. 62 
ACKNOWLEDGEMENT .................................................................................... 63 
REFERENCES .................................................................................................. 65 
 
iv 
ABBREVIATIONS 
ADA American Diabetes Association 
AMI acute myocardial infarction 
AN autonomic neuropathy 
ARB angiotensin II receptor blockers 
BG blood glucose 
BMI body mass index  
CACTI The Coronary Artery Calcification in Type 1 Diabetes study 
CDR  Cause of Death Registry 
CGM continuous glucose monitoring 
CHD coronary heart disease 
CI confidence intervals 
CKD-EPI Chronic Kidney Disease Epidemiology Collaboration 
CRU  clinical research unit 
CSII  continuous subcutaneous insulin infusion 
CVD  cardiovascular disease 
DCCT  The Diabetes Control and Complications Trial 
EDC Epidemiology of Diabetes Complications 
EDIC  Epidemiology of Diabetes Interventions and Complications 
eGFR estimated glomerular filtration rate 
ESRD end-stage renal disease 
FDA Food and Drug Administration 
 
v 
FGM  flash glucose monitoring 
GEE Generalized Estimating Equations 
HbA1c Glycosylated Haemoglobin 
ICF  informed consent form  
IFCC International Federation of Clinical Chemistry 
IPR Swedish Inpatient Registry 
LEA  lower extremity amputation 
 
LISA Longitudinal Integration database for health insurance and 
labor market studies 
MAD  mean absolute difference 
MARD mean absolute relative difference 
MDI multiple daily injections 
MI myocardial infarction 
NDR National Diabetes Registry 
NGSP National Glycohaemoglobin Standardization Program 
OR  odds-ratios 
PDR  Prescribed Drug Registry 
PKC protein kinase C 
RAAS renin–angiotensin–aldosterone system 
T1D  type 1 diabetes 
 
T2D  type 2 diabetes 
UKPDS UK prospective Diabetes Study Group 
WHO  World Health Organization 
  
 
vi 
FOREWORD 
Working at the emergency department gave me many opportunities to meet 
people and families hearing "diabetes" for the first time in that unwanted 
personal way. Some of them are frightened and wondering what is going to 
happen to them, others having an infinite number of questions from the first 
moment or asking if their lifestyle has had an impact on their health in such a 
bad way. I met patients who believed that medicine is so powerful that 
nowadays we can cure diabetes like pneumonia. I would love to give that hope, 
but keep thinking for myself: "Nothing in life is to be feared, it is only to be 
understood. Now is the time to understand more, so that we may fear less." ― 
Marie Curie. I met young people who have been ignoring their new life with 
diabetes and all the rules. 
Apparently, a patient and a healthcare provider often have different 
perspectives on the same topic. I would like to help us to come closer to each 
other. I believe that science can battle some fears and I hope that this thesis 
will bring closer to the answer to one of most essential patient questions like: 
do I have a chance to live MY life? 
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1 INTRODUCTION 
1.1 RATIONALE 
According to WHO report, in 2014 approximately 422 million adults aged over 
18 years were living with diabetes (1). It is not always easy to differentiate 
between type 1 and type 2 diabetes (2). Thus, it requires evaluating pancreatic 
function, for example, to measure C-peptide levels to estimate insulin secretion 
capability (3). The most significant biomarkers of type 1 diabetes are 
autoantibodies. The 65kDa form of glutamic acid decarboxylase (GAD65), 
[pro]insulin, insulinoma antigen 2 (IA-2), zinc transporter 8 (ZnT8), 
tetraspanin 7 are identified as molecular targets in type 1 diabetes (4). There is 
no precise global prevalence of type 1 diabetes (1). Type 1 diabetes accounts 
for 5% to 10% of all diabetes cases (5). Epidemiology in middle and low-
income countries is not studied enough (6). However, type 1 diabetes is the 
major public health problem and affects millions of people globally. We live 
in the era of fast-developing technologies, knowledge of T1D management 
grows exponentially, but type 1 diabetes is still challenging health care. The 
European region currently has the highest prevalence of T1D in children of any 
area in the world (1); diabetes is not "curable," it continues into adulthood.  
The costs associated with diabetes account for approximately 10% of the entire 
European public health care expenses (7). Severe hypoglycemic events are 
associated with emergency healthcare resource use and economic costs. 
Diabetes complications (micro- and macrovascular) account for a significant 
part of these costs (8). Glycosylated hemoglobin (HbA1c), an estimate of the 
mean glucose level over the last 2-3 months, is closely associated with the 
development of diabetes complications (9). A Scottish study showed that of 
the modifiable risk factors, HbA1c was the most critical cost driver in T1D 
(10). Well known is that HbA1c levels correlate with the risk of long-term 
diabetes com-plications (9, 11) - which is the most severe obstacle to mortality 
reduction in the target population.   
Euro Diabetes Index 2014 ranked Sweden as the country with the best diabetes 
care delivery in Europe (12). However, according to NDR year rapport (2016), 
just 21.2% of adult persons with type 1 diabetes achieved targets for good 
glycaemic control (HbA1c<52 mmol/mol) and 20.1% of adult persons with 
type 1 diabetes in Sweden have inadequate glycaemic control (HbA1c>70 
mmol/mol) (13). We know that glycemic control has changed during the last 
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few years for the better: in 2012, 30% of T1D patients had very poor glycemic 
control (13).  
 
Despite this apparent improvement of diabetes management, a critical need to 
understand how to improve glycemic control remains. Therefore, we 
formulated the following points of interest: 
- To support the intensive treatment strategy, diabetes care 
guidelines recommend monitoring HbA1c at least every third month in patients 
with glycemic control above the target. To our knowledge, there are few 
studies evaluating to what extent these guidelines are followed. 
- A multicentre observational study over 5 years reported that 
switching treatment from MDI to CSII was associated with improved HbA1c. 
This effect decreased however significantly with time, from a relative 
reduction in HbA1c of 4.6 mmol/mol (≈ 0.42%) at 1 year to 2.2 mmol/mol (≈ 
0.2%) at five years of treatment (14). In what subgroup of persons, a greater 
beneficial effect on HbA1c can possibly be sustained over time has not been 
evaluated and is another question to answer to optimize diabetes care.  
- Continuous glucose monitoring (CGM) is an increasingly 
common tool to manage glycemia. There are recommendations on when to 
consider CGM treatment, but in our knowledge, there are no official 
recommendations for selecting a particular CGM system. Is any CGM device 
more precise at different glucose levels than others, primarily when 
hypoglycemia occurs? At the time of designing a study, we could not find any 
clinical trials comparing patient’s subjective experience with different CGM 
Viktorija Matuleviciene Anängen 
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systems. Both these questions may play a role also for treatment effect and 
compliance. 
The "renaissance" of diabetes care occurred in the last decades of the 20th 
century and resulted in the perceptible difference to the continuous 
improvement in life expectancy. Cardiovascular disease (CVD) is the most 
common cause of death in persons with type 1 diabetes (15, 16). 
Cardiovascular disease event occurs earlier in persons with T1D than in the 
general population. Epidemiological studies support the relationship between 
inadequate glycemic control and cardiovascular events (3). Recent studies 
suggest that effects of good glycemic control on cardiovascular risk may be 
more complicated. Optimally managed glycemia solely may not provide the 
desired cardiovascular risk reduction. Thus, risk might depend on other factors, 
such as age, gender, diabetes duration and diabetic kidney disease. (3, 17, 18). 
The excess risk of AMI in persons with T1D since new guidelines of intensive 
management of diabetes mellitus and improvement regarding the treatment of 
CVD risk factors such as hyperlipidemia and hypertension were implemented 
in Sweden has not been estimated. Evaluation of how the excess risk of major 
coronary events varies as a function of glucose control and presence and 
severity of renal complications in persons with T1D is another question on 
target. 
Since the prevalence of type 2 diabetes in the global perspective is increasing 
significantly (1), it is easy to underrate the needs of the 5-10% of patients with 
type 1 diabetes. I believe this work could lead to better understanding of T1D 
treatment and guide management for improved outcomes in T1D patients.    
Structure of the thesis  
The thesis frame is divided into two parts: modern treatment and risk of major 
coronary events. The light grey box indicates the summary of the chapter. 
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1.2 TYPE 1 DIABETES, HISTORICAL 
MOMENTS 
The first written records of diabetes come from ancient Egypt around 1500 BC 
described as "too great emptying of the urine" (19). However, as the defined 
medical condition diabetes history is counting just a little bit more than 140 
year. In the late XIX century, Etienne Lancereaux characterized diabetes as a 
syndrome and observed that some diabetes patients live many years while 
others die within 2-3 years (20). This understanding gave a basis for the 
modern rough breakdown of diabetes to type 1 and type 2. 
Type 1 diabetes is caused by the deterioration of insulin-producing pancreatic 
Beta cells (21). Some years ago, age was one of the most important criteria to 
diagnose type 1 diabetes.  
Figure 1. Type 1 diabetes. Natural history. Adapted with the permission after reference 21 
Type 1 diabetes generally manifests in children or teenagers. However, it is 
more evident now that type 1 diabetes can occur at any age, and recent studies 
show that in certain individuals residual C-peptide can be detected many years 
after the initial diagnosis was made (21, 22). An even more challenging aspect 
of diabetes is that children may get type 2 diabetes. The exact cause for type 1 
DM is not known. Natural history of type 1 diabetes is presented in figure 1. 
Genetic factors are identified to contribute to the susceptibility of developing 
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T1D. Over 20 genes have been found to influence the susceptibility to the T1D 
(23). Despite it, almost 90% of the newly diagnosed T1D cases have no family 
history (24, 25). Men and women have the same risk (26). 
The key sign of type 1 diabetes is the need for insulin treatment due to de-
creased insulin secretion, which causes hyperglycemia. The typical clinical 
manifestation of this disease is polyuria, polydipsia and weight loss. Some-
times the first identifiable sign of T1D may be ketoacidosis. Ketoacidosis is an 
acute life-threatening complication of diabetes caused by reduced insulin 
levels. 
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1.2.1 INSULIN DISCOVERY 
 
Insulin was discovered in the early thirties (27). Bunting (unknown surgeon at 
that time) has formulated an idea and convinced the diabetes coryphaeus prof. 
J.Macleod (working in Canada), to start the experiment. The central part of the 
investigation was stopping the flow of nourishment in the pancreatic duct 
which led to damage in the cells producing digestive enzymes, but not islets of 
Langerhans, in dogs. Thus, insulin could be extracted. The experiment started 
in 1921 (27, 28).  By the end of the year, the group already worked on purifying 
of insulin.   
The team desired to start experiments in humans. As soon as in 1922 in 
Toronto, Canada, Leonard Thompson (a 14-year old diabetes patient), received 
insulin injections (28). Thompson's health improved. Also, already in February 
insulin was administered to 6 more patients. Leonard Thompson received 
insulin for 13 years and died of pneumonia at the age of 27 (28, 29). 
After just two years, insulin production was extended. There was produced 
enough insulin to supply the North America continent (29). In 1923 the Nobel 
Committee decided to award Banting and Macleod the Nobel Prize in 
Physiology or Medicine (29). Insulin with longer duration of action was 
introduced in the 1930s; a lot was done to improve the purity of insulin (26). 
However, not until the 1980s was the first insulin of human amino-acid 
sequence was introduced to the market. 
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Table 1. Available insulin formulations (30). Peak and duration of action are 
dose-dependent and may vary from times listed in the table. 
 
1.2.2 MAJOR TECHNICAL ACHIEVEMENTS 
In 1969 blood glucose meters became available. (31) 
In 1976 the first wearable continuous subcutaneous insulin infusion was 
developed (insulin pump therapy). (31) 
In 1999, the Food and Drug Administration approved the first CGM device in 
the USA. It was called the continuous glucose monitoring system (CGMS) and 
manufactured by Medtronic MiniMed (Medtronic Diabetes, Northridge, CA). 
Readings were available to review by physicians only after recording interval 
of 72 hours, retrospectively. (32) 
In 2016, the Food and Drug Administration approved the first hybrid closed-
loop system (Medtronic MiniMed 670G) that continuously tracks glucose 
levels and adapts insulin delivery. (33) 
Insulin Onset of 
action 
Peak of 
action 
Duration of action 
Rapid-acting 
Insulin lispro (Humalog) 
Insulin glulisine (Apidra) 
Insulin Aspart (NovoRapid) 
 
 
10-15 min 
 
 
 
 
0,5-3 h 
 
 
 
 
3-5 h 
 
 
Insulin Aspart (Fiasp) 5-10 min 1h 3-5 h 
Short-acting 
-Humulin regular 
30-60 min 2-4h 5-8 h 
Intermediate-acting 
(NPH) 
60-120 min 4-10 h 10-16 h 
Long-acting 
-Insulin detemir (Levemir) 
-Insulin glargine (Lantus) 
-Insulin degludec (Tresiba) 
60-180 min minimal peak 17-24 h 
 
 
24 + h 
Type 1 diabetes in adults: modern treatment and risk of major coronary events 
8 
1.2.3 BEYOND THE BASICS 
The exact number of patients with type 1 diabetes in the world is not known 
(1). Only a few countries have established appropriate registries. 
Approximately 78000 youths are diagnosed with type 1 diabetes every year 
worldwide (34). The incidence varies a lot among countries. The lowest 
incidence of T1D is in East Asians and Native Americans, the highest - in 
Finland, Sardinia, and Sweden (20). A higher than 350-fold difference in the 
incidence of T1D among the 100 different populations worldwide was reported 
(34). However, the latest observations show a rapid change in incidence of type 
1 diabetes among a genetically stable population (for example, in mainland 
China incidence in-creased from 0.57:100000 person-years to 3.36:100000 
person-years) (35) which may mean that other factors (non-genetical) have an 
impact on high morbidity. The understanding of these changes in the global 
and not least historical perspective is crucial for the chances to achieve the 
successful health-care. 
The American Diabetes Association (ADA) has been actively working with 
creating and spreading of obtained knowledge in diabetes healthcare standards, 
based on the quality of evidence (34). However, health care for type 1 diabetes 
patients differs from country to country. The healthcare situation in 
economically weak countries possibly may be comparable to that in Sweden 
several decades ago. In the USA more than 98% of persons with type 1 diabetes 
live longer than six years after the diagnosis, in sub-Saharan Africa - just 1% 
of patients with newly diagnosed type 1 diabetes can expect to live for the next 
six years (36). Life expectancy in Mozambique is approximately seven months 
after type 1 diabetes is diagnosed (36). These vast differences in life 
expectancy depend on the economic realities of insulin accessibility. 
In the USA more than 98% of persons with type 1 diabetes live longer than 
six years after the diagnosis, in sub-Saharan Africa - just 1% of patients with 
newly diagnosed type 1 diabetes can expect to live for the next six years (36). 
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2 DIABETES CARE TODAY: HBA1C, 
CARDIOVASCULAR COMPLICATIONS 
AND TECHNICAL DEVICES 
2.1 HBA1C TESTS 
HbA1c reflects the mean glycemia over the approximately 120 days period 
(erythrocyte lifetime) and is widely used for the routine monitoring of long-
term glycemic status in patients with type 1 diabetes (37, 40, 54). Multiple 
studies show the strong association between HbA1c levels and micro- and 
macrovascular complications of diabetes mellitus (10, 15, 38). HbA1c values 
are also used as the indicator of the quality of diabetes care. In Sweden, 
approximately 1.2 million HbA1c tests are performed annually (39). More than 
100 different commercial tests have been developed to measure HbA1c (40). 
It raised concerns about the accuracy of measurements which is needed for 
strict quality management. Insights from the DCCT, and the UK prospective 
Diabetes Study Group (UKPDS) studies raised the necessity of an accurate, 
precise HbA1c assay (41). In 1997, a nationwide standardization was 
introduced. In 2001, IFCC HbA1c reference method approved. The major 
statement is that all values are to be converted and reported in SI units 
(mmol/mol) and derived National Glycohaemoglobin Standardization 
Program (NGSP)/DCCT units (40). In 2007 IFCC and clinical organizations 
agreed to use these units. In Sweden, the performance of locally measured 
HbA1c is monitored by Equalis through external quality assessment schemes 
(42). The National Board of Health and Welfare recommended HbA1c goal 
for nonpregnant adult with type 1 diabetes is below 52 mmol/mol (43). 
Distribution of HbA1c levels in adult persons with T1D in Sweden is presented 
in figure 2. 
According to UK type 1 diabetes management guidelines, HbA1c should be 
checked twice yearly in adult (≥18 y.o.) patients who are meeting treatment 
goal HbA1c ≤52 mmol/mol and every three months in patients whose therapy 
is being modified or who are not achieving the goal (44) Similar 
recommendations are provided by ADA (45).  Swedish guidelines have not 
specified the frequency of HbA1c measurements in adult persons with type 1 
diabetes (43). In very elderly or limited lifespan as well as in those T1D 
patients with a high risk for severe hypoglycemia, the HbA1c goal can be less 
stringent (46). Results from a British study examining repeat HbA1c tests from 
three clinical laboratories in 79409 persons with diabetes (both T1D and T2D) 
showed that in a subgroup of persons with an inadequate glycemic control 
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(HbA1c ≥53 mmol/mol) testing HbA1c every third month was associated with 
a 3.8% reduction in HbA1c compared with a 1.5% increase detected with 
testing HbA1c once per year (47).  
 
Figure 2. Distribution of HbA1c levels in adult persons with T1D in Sweden (13) 
There is no high-quality evidence for the optimum frequency of HbA1c 
monitoring in the clinical practice (48).  Adherence to the HbA1c testing 
frequency in T1D is not studied enough. Most of the previous research focused 
on persons withT2D or included patients regardless of the type of diabetes. In 
brief, J.Lian found that only 12.36% of T2D patients met the ADA 
recommended HbA1c testing frequency (49). A large retrospective study from 
Australia reported that about 58.3% of the T2D patients did not have the 
recommended HbA1c tests (50). In another significant study from the UK, 
Driskell OJ. reported that just 49% of HbA1c test requests conformed to 
guidance and highlighted both over-requesting and under-requesting it (51). 
Suboptimal HbA1c testing in children and youth with diabetes is also reported 
(52). We could not find studies evaluating the sociodemographic predictors of 
HbA1c testing among T1D patients.  
Many studies prove the association between HbA1c and diabetes 
complications. According to treatment recommendations, if the therapy has 
been modified or HbA1c is not meeting the target levels of 52 mmol/mol, 
the HbA1c check should be done every three months. Evidence supports 
recommendations. However, most of the studies are performed in patents 
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with type 2 diabetes. Some studies show non-adherence to the guidelines in 
terms of HbA1c testing frequency.   
 
2.1.1 CONDITIONS THAT MAY AFFECT HBA1C 
LEVELS 
Conditions that reduce red-blood cells lifespan, or decreases their mean age, 
falsely lower HbA1c test results (53, 54): bleeding, hemoglobinopathies, 
hemolysis, renal anemia and vice versa. Conditions that increase the mean age 
of circulating erythrocytes may affect HbA1c in the opposite direction, in other 
words elevate HbA1c levels. Most studies investigating the effect of anemia 
on HbA1c are limited to the small sample groups, but data support that iron 
deficiency may lead to elevated HbA1c levels (54). The mechanism through 
which iron deficiency influences HbA1c is not fully understood. Several 
investigators found that effect of iron deficiency on HbA1c depends on the 
degree (55, 56) of anemia and some studies suggest that in mild anemia cases 
effect on HbA1c may lack in clinical relevance (57). Iron deficiency is highly 
common in the world and affects more than 30% of the population, especially 
women of childbearing age, approximately 4-12% of women have anemia. 
Diabetic patients, especially with inadequate glycemic control are at the higher 
risk to develop chronic kidney disease, which in its turn can cause anemia. The 
role of glycemic control and the value of HbA1c in these patients are 
controversial and need further investigation. Few studies investigated the 
effect of iron supple-mentation or erythropoietin therapy on HbA1c levels in 
patients with type 1 diabetes. Most of the studies investigated effect in persons 
without diabetes or in persons with type 2 diabetes showing that iron and 
erythropoietin-stimulating agents caused the fall in HbA1c values (58-60). 
Anemia seems to be a factor to consider before making a therapy decision 
based solely on HbA1c levels.   
 
2.1.2 WHY GLUCOSE LEVEL MATTERS? 
Vascular complications of type 1 diabetes (such as retinopathy, nephropathy, 
and ischemic heart disease) are the unfavorable manifestations of diabetes.  
Glycemia has been shown to be one of the strongest risk factors of future 
microvascular and macrovascular complications (10, 11, 15, 64). 
Unfortunately, the precise mechanism is not fully understood. It has been 
discussed that some of the tissues are prone to be damaged by chronic 
hyperglycemia, but others are not (61). It has been suggested that it may 
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depend on the capability to maintain the constant concentration of the glucose 
in the cell (61). 
 
 
Figure 3. Vascular and interstitial tissue damage causing pathways. 
 
Vascular and interstitial tissue damage is caused by at least four different 
pathways (61) (shown in figure 3): 
1. Polyol pathway 
2. Hexosamine pathway 
3. Advanced glycation end-products formation 
4. Protein kinase C (PKC) pathway 
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1. Increased polyol pathway (61, 62) leads to oxidative stress due 
to the ac-cumulation of sorbitol and fructose. Sorbitol is highly hydrophilic and 
cannot diffuse through the cell membrane unimpeded and causes 
hyperosmolarity which for its part induces oxidative stress (62). 
2. Increased hexosamine pathway flux increases the formation of 
proteo-glycans, glycolipids and some other toxic metabolites, increases the 
expression of TGF-beta and causes alterations in the gene expressions. This 
leads to vascular endothelial dysfunction (62, 63). 
3. Increased intracellular formation of advanced glycation end-
products arises from intracellular oxidation of glucose to glyoxal and 
fragmentation of glyceraldehyde-3-phosphate and dihydroxyacetone 
phosphate to methylglyoxal. This alters the functional properties of several 
matrix proteins and promotes the synthesis of growth factors and cytokines 
(62). 
4. Intracellular hyperglycemia increases the amount of DAG, 
which activates PKC. It is suggested that PKC by depressing nitric oxide 
production and increasing activity of endothelin-1 causes blood flow 
abnormalities. Activation of PKC contributes to increased permeability of 
endothelial cells and micro-vascular matrix protein accumulation (61, 62). 
Despite these systemic factors, organ-specific factors are also crucial in the 
pathogenesis of diabetes-specific complications. 
Continuously high blood glucose levels lead to changes on the molecular 
level in some tissues and manifest the condition of vision impairment, 
kidney dam-age, and loss of sensation. There are four central pathways of 
tissue damage. 
 
Clinical effects of hyperglycemia 
So far, the previous chapter has focused on pathways triggered on 
hyperglycemia. The current chapter will discuss clinical effects of chronic 
hyperglycemia. A considerable amount of literature has been published on 
T1D complications.  The impact of T1D complications on patients’ quality of 
life is significant (3, 157), and a critical need to understand how to reduce risks 
is still an important issue. Many studies pay particular attention to the effects 
of glycemic control. Evidence shows that good glycemic control in the early 
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stage of the disease, reduces the risk of complications (10, 11, 64)). One of the 
most important studies in the field, the Diabetes Control and Complications 
Trial (DCCT) was con-ducted between 1983 and 1993 and designed to 
determine whether intensive treatment would delay or prevent complications 
in T1D patients. The adjusted mean risk of development of retinopathy in the 
primary prevention cohort (T1D patients with no previous retinopathy) was 
reduced by 76% (11). The risk of microalbuminuria decreased by 34%, and 
neuropathy by 69% (11). DCCT study participants were offered to continue 
participating in the follow-up study –Epidemiology of Diabetes Interventions 
and Complications (EDIC). The long-term treatment effects on microvascular 
and macrovascular complications were evaluated (64). Intensive treatment had 
the beneficial effect on the incidence of both micro- and macrovascular 
complications. Several other studies reported evidence on the association 
between hyperglycemia and diabetes complications (10, 15, 38, 65). 
DCCT/EDIC studies showed, that higher HbA1c levels at the baseline and 
during follow up period were associated with hypertension (66, 67). 
Hypertension contributes to the development of microvascular complications 
(68) and may mediate the risk of cardiovascular complications (67). 
How high levels of blood sugar affect your body? High levels of glucose are 
unhealthy for your body. If high glucose levels persist, it can cause changes 
in blood vessels. Blood vessels become hardened and narrowed. This makes 
difficult for blood to flow through them. Consequences of it: impaired vision 
(in extreme cases even vision loss), kidney damage, nerve damage, which 
causes pain, loss of sensation. Larger vessels may be affected as well, and it 
may lead to a heart attack. Vessels that supply blood to the limbs also may 
be affected. The worth effect of damage in the large vessels may be an 
amputation of the limb or even death. Good glycemic control (in clinical 
studies achieved by using intensive insulin treatment such as multiply daily 
injections or insulin pump) significantly reduces the risk of vision 
impairment, kidney damage, and nerve damage. 
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Figure 4. Risk factors associated with microvascular and macrovascular 
complications in T1D (1, 3, 15, 45, 115-116, 166) 
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2.2 CARDIOVASCULAR COMPLICATIONS 
2.2.1 CARDIOVASCULAR COMPLICATIONS IN T1D 
In the World Health Organization (WHO) multinational cohort, cardiovascular 
disease (CVD) accounted for 44% of T1D deaths (69). A nationwide registry-
based Swedish study with 33 915 T1D patients and 169 249 matched controls 
reported that 2.7% of persons with T1 diabetes and 0.9% of matched controls 
died from cardiovascular causes (34). The mean follow-up was 8.0 and 8.3 
years and the mean age was 35.8 years and 35.7 years in the T1D and matched 
control groups, respectively. According to a UK study, T1D patients aged over 
65 years have a CVD prevalence of 39.5% (70). In a Danish study with 4821 
T1D patients, CVD was the main cause of death, 31% and 30% of all death for 
men and women, respectively (71). Several studies reported no significant 
difference in incidence of cardiovascular disease in men and women with T1D, 
the female sex protection seen in the general population was not observed in 
T1D (3, 72-75). Overall, T1D patients experience CVD more often (3, 15) and 
earlier than persons without diabetes, when types of CVD are separated, 
coronary heart disease (CHD) predominates (3, 15, 75). 
Children, adolescents, and adults with T1D have increased the thickness of 
carotid intima-media and elevated plaques compared to healthy age and sex-
matched controls (76). The altered endothelial function is observed in T1D 
even at an early stage of disease and even in patients without detectable 
atherosclerotic changes (77). Studies prove that risk factors such as diabetes 
duration, glycemia, dyslipidemia, smoking, albumin excretion rate are 
associated with intima-media thickness and that the major factor triggering the 
development of endothelial dysfunction is hyperglycemia (76). It has also been 
reported that endothelial dysfunction is more severe in patients with presence 
of microalbuminuria (17). The Pittsburg Epidemiology of Diabetes 
Complications (EDC) study reported that patients with dysfunctional 
endothelium have the higher risk to develop coronary heart disease (78). It is 
known that endothelial dysfunction leads to the development of atherosclerotic 
changes in the vessels (79). When CHD occurs clinically, the 
pathophysiological process of atherosclerosis is very advanced. 
2.2.2 THE ROLE OF GLYCEMIC CONTROL IN CVD RISK  
A Norwegian study, carried out during over 18 years follow-up period 
prospectively evaluated atherosclerotic changes in coronary vessels with 
intravascular ultrasound and found strong correlation between atheromatosis 
and HbA1c, where 1% (≈10 mmol/mol) increase in HbA1c was associated with 
6.4% coronary artery stenosis (80). Epidemiological evidence generally 
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supports the association between hyperglycemia and clinical coronary heart 
events (3). A registry-based Swedish study reported the strong association 
between HbA1c and coronary artery disease in a T1D population, showing 
progressively increasing risks for CHD and CVD with higher HbA1c (81). A 
Finnish study carried out over an 18 years long follow-up period showed that 
CVD mortality in middle-aged (at the baseline) patients with type 1 diabetes 
increases by about 50% with every 1% (≈10 mmol/mol) increase of HbA1c 
(82). Similar results were shown in a population-based cohort of 879 patients 
with T1D from Wisconsin: hyperglycaemia was associated with 
cardiovascular mortality in a dose-dependent manner. Association between 
hyperglycemia and cardiovascular mortality remained even when glycemia 
was analyzed as a continuous variable (65).  
The importance of strict glycemic control to protect against macrovascular 
complications in T1D has been established among other things in the DCCT/ 
EDIC studies. Despite the young age of the participant at the baseline (13 to 
40 years at the time of randomization) (11), a long follow up period (mean 17 
years) (83) allowed to evaluate cardiovascular risk in the cohorts. The amount 
of non-fatal and fatal cardiovascular events in the intensive treatment group 
was lower compared to the conventional treatment group (11, 64, 83). The risk 
of any cardiovascular disease event in the intensive treatment cohort was 
reduced by 42 percent. It is important to note that the difference in HbA1c from 
the end of the DCCT (1993) study (57.4 mmol/mol (7.4%) in the intensive 
treatment and 76.1 mmol/mol (9.1%) in the conventional treatment group) to 
year 11 in the EDIC (2004) has attenuated and was 62.8 mmol/mol (7.9%) and 
61.7 mmol/mol (7.8%) respectively (11, 84). It is likely that glycemic control 
in the early years of T1D may play an essential role in the prevention of future 
complications. The DCCT/EDIC Research Group reported that for 1% (≈ 10 
mmol/mol) increase in mean HbA1c, the risk for or major atherosclerotic 
cardiac event increased by 42% (85).  
However, not all previous studies reported the association of inadequate 
glycemic control with cardiovascular morbidity and mortality, which may 
indicate that other pathways than effects of glycemic control should also be 
taken in to account (86, 87). Looking from the other perspective, according to 
a recent epidemiological registry based (NDR) study, among 18450 type 1 
diabetes patients, 1023 had >50 years diabetes duration. A third part of those 
patients (N=319) had no history of CVD, kidney disease or severe retinopathy. 
The study reports that these patients were younger and had lower HbA1c 
compared to those who developed CVD (88). 
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2.2.3 THE ROLE OF DIABETIC NEPHROPATHY IN CVD RISK 
Chronic kidney disease is defined as functional or structural abnormalities of 
the kidneys, persisting for at least three months (89). Diabetic nephropathy is 
one of the microvascular complications of DM. Studies show a strong 
association of it with cardiovascular disease, but this relationship is not fully 
under-stood (89, 90). Chronic kidney disease is one of the frequent exclusion 
criteria for participation in major cardiovascular trials. Out of 86 trials, more 
than 80% excluded patients with end-stage kidney disease and 75% excluded 
patients with chronic kidney disease (91). This may contribute to a lack of 
evidence for potential treatment choices. It is known that a person with chronic 
kidney dis-ease (stage 3) has a higher critical risk of death than progressing to 
end-stage renal disease (ESRD) (92). Albuminuria is identified as a strong 
prognostic marker in the T1D population. Microalbuminuria is usually 
considered as the early manifestation of diabetic nephropathy, but its presence 
alone does not confirm established kidney disease (18). Approximately 15 
years after diabetes diagnosis, 20-30 percent of patients develop 
microalbuminuria (93, 94). 
Microalbuminuria is defined as two of three positive samples with an albu-
min/creatinine ratio of 3-30 mg/mmol (≈30-300 mg/g) or U-albumin of 20-
200µg/min (20-300 mg/l). Macroalbuminuria is defined as two of three 
positive samples with an albumin/creatinine ratio >30 mg/mmol (≈ >300 
mg/g) or U-albumin >200µg/min (>300mg/l). Albuminuria should be 
confirmed in the absence of urinary tract infections (95). 
 
Several studies observed regression of albuminuria with appropriate treatment 
and control of risk factors (96, 97). The strongest modifiable factors, associated 
with improvement of albuminuria were lipid status (low level of cholesterol 
and/ or triglycerides) and glycemia (HbA1c < 63.9 mmol/mol (<8%). 
Microalbuminuria of short duration is more likely to regress than 
microalbuminuria of long duration. However, this improvement cannot 
guarantee preserved kidney function (98), non-albuminuric diabetic 
nephropathy is now well recognized (99).  Increased HbA1c, systolic blood 
pressure, early glomerular filtration rate decline, serum uric acid, duration of 
diabetes, age and the presence of concomitant microvascular complications are 
associated with progressive diabetic nephropathy (100).  
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Methods of estimating kidney function:  
Estimated glomerular filtration rate (eGFR). May be calculated using 
exogenous (inulin and iothalamate) and endogenous (urea and creatinine) 
sub-stances.  
CKD-EPI equation - assumed to be more precise than the MDRD study 
equation and may reduce false-positive results (100).   
a) CKD-EPI Creatinine*,  
b) CKD-EPI Cystatin C**  
c) CKD-EPI Creatinine and Cystatin C*** 
MDRD study equation 
* National kidney foundation recommended method for estimating GFR in 
adults (102). 
** Cystatin C considered to be less affected by patients age and weight than 
creatinine-based measurements and is the better predictor of micro- and 
macrovascular complications (103, 104). Cystatin C is not superior to serum 
creatinine to estimate acute changes in kidney function. Clinical use remains 
limited. 
*** studies show that combining Cystatin C and creatinine as well as age 
and sex factors, GFR estimation may be most precise (101, 105). 
 
ACE inhibitors and angiotensin II receptor blockers (ARB) are even in the 
absence of hypertension used to decrease microalbuminuria (106). The renin–
angiotensin–aldosterone system (RAAS) blocking agents (ACE inhibitors and 
ARB) may cause an acute but transient decrease in glomerular filtration rate 
(GFR)due to the reduction in glomerular hyperfiltration, usually detected by 
measuring elevated creatinine levels. Both ACE inhibitors and ARB have an 
important role in the prevention of progression of renal disease (107) and 
changes in coronary arteries (108). Before angiotensin inhibition along with 
intensive glycemic control was implemented in daily treatment routines, the 
incidence of developing overt nephropathy and ESRD was high, up to 35% of 
study participants developed ESRD (109, 110). Incidence rate has declined 
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substantially over the years, and recent studies report that the long-term 
cumulative incidence of overt nephropathy and ESRD has decreased and is 
lower than 10% (109, 111-112). A Large Finnish study estimating ESRD in a 
T1D population reported a cumulative incidence risk of ESRD of 2.2% and 
7.8% at 20 and 30 years after diagnosis respectively (112). The DCCT/EDIC 
studies reported that in individuals with over 30 years of diabetes duration less 
than 2% (10 of 711) of the subjects in the intensive treatment group had 
developed renal insufficiency and that 6% of the DCCT/EDIC population 
developed declined renal function (eGFR <60 mL/min/1.73 m2) (113).  A 
recent Italian study, evaluating 2656 patients with type 1 diabetes, reported that 
3.7% of patients with diabetes duration 11-20 years and 8% of patients with 
diabetes duration >30 years developed declined renal function (114).  
Several studies have linked diabetic nephropathy with an increased risk of 
coronary heart disease (115-116), both albuminuria and decreased eGFR have 
been identified as risk factors for cardiovascular mortality even in the general 
population (117, 118). It has been reported that patients with chronic kidney 
disease stage 3 have nearly ten times higher risk of death than the risk of 
progression to ESRD (119). Traditional risk factors for CVD and 
hypercoagulable conditions may play a role in it (89). It has been speculated 
that kidney damage may reflect more general vascular damage in the 
cardiovascular system which leads to higher cardiovascular disease and 
mortality risks (120). Other factors as a contribution to insulin resistance, 
inflammation, hypertension, dyslipidemia play a role in the mechanisms of 
CVD in patients with diabetes.  
Figure 5. Overview of major established and proposed mechanisms of CVD in 
patients with DM and CKD. Adapted with permission after reference 89. 
In line with previous reports, the association between glycemic control and 
mortality in patients with kidney transplant has been reported (121). Taking 
optimal glycemic control perspective in an account, it should be mentioned 
Viktorija Matuleviciene Anängen 
21 
that patients with CKD experience hypoglycemia more often than patients 
without CKD (122). Chronic kidney disease is seen as the dominant 
contributor to excess mortality in type 1 diabetes and prevention of it is 
essential to reduce the risk of premature mortality (123). On the other hand, in 
the past several decades observed decreased incidence rate in kidney disease 
among T1D patients had not been accompanied by a corresponding decline in 
CVD (3).   
Overall, persons with type 1 diabetes experience cardiovascular disease 
more often than persons without diabetes. Initial changes in blood vessels 
may be detected already in children and adolescence. Previously performed 
studies generally support the association between inadequate glycemic 
control and clinical coronary heart events (such as myocardial infarction). 
Persons with type 1 diabetes and renal complications have increased risk of 
coronary heart disease. 
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2.3 DIABETES CARE TODAY: TECHNICAL 
IMPLEMENTATION 
2.3.1 ADHERENCE/NON-ADHERENCE TO INSULIN 
TREATMENT 
Currently, in developed countries intensive insulin therapy regimens for 
T1DM most commonly are delivered by multiple daily injections (MDI) of 
long-acting basal insulin and short- or rapid-acting prandial insulin 
formulations. The DARTS Medicines Monitoring Unit reported that HbA1c 
and diabetes complications are related to inadequate insulin treatment (124).  
 
Figure 6. Some factors affecting adherence to insulin treatment regimen (124-126) 
 
Non-adherence to an insulin treatment regime is common and ranges from 23-
77% (125). This makes it difficult to achieve HbA1c targets and has other 
consequences.  The Joslin Behavioural Research group found that 30.5% of 
T1D patients in their study self-restricted insulin (N=234 women, follow up 
period 11 years) (126). At baseline, they were younger and had higher HbA1c 
levels (HbA1c 81 mmol/mol (NGSP 9.6%) in comparison to 67 mmol/mol 
(NGSP 8.3%) among non-restrictors). By the study results, inadequate insulin 
treatment increased the relative risk of death by 3.2 times. Some of the 
previously named factors influencing the adherence to insulin regimen may be 
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controlled, at least partially, by using continuous subcutaneous insulin infusion 
therapy. 
2.3.2 SUBCUTANEOUS CONTINUOUS INSULIN INFUSION 
THERAPY (INSULIN PUMP) TREATMENT  
In healthy individuals, insulin is produced continuously during the day (basal 
insulin), in response to meals additional prandial (bolus) secretion of insulin 
occurs. Modern treatment aims to recreate physiological fluctuation in insulin 
concentrations during the day (127). Today the most optimal way for patients 
to deliver insulin is the subcutaneous injection/infusion (other technically 
possible insulin delivery routes are: intravenous, inhaled, intraperitoneal). The 
whole conception of insulin pumps is to imitate physiological insulin 
concentrations by combining basal and bolus insulin delivery. An insulin pump 
is a portable; battery operated computerized medical device which is attached 
to a disposable insulin reservoir and infusion set (127). The insulin is carried 
through an adjustable tube connected to a catheter that is inserted preferably in 
the abdominal area, upper outer quadrant of the gluteal area. The upper thigh 
area and the triceps fat pad may also be used (127). Insulin delivery consists 
of basal insulin (the minimum amount of insulin is needed to maintain 
glycemia in the target range without inducing hypoglycemia and suppressing 
ketogenesis and gluconeogenesis) and bolus insulin (to control glycemia 
during mealtimes), figure 7. 
 
Figure 7. Schematic explanation on principle of insulin pump. 
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Insulin pumps have been used for more than 35 years (45). According to NDR 
2016-year rapport, 22.7% of all adult T1D patients are using insulin pump (13). 
Insulin pump was one of the chosen methods for intensive treatment arm in the 
DCCT (11). Devices were large and had technical difficulties. Rapid 
technological progress meets requirements and have introduced color touch 
screen, USB-rechargeable batteries, pre-filled insulin cartridges, tubeless 
pumps and being waterproof. 
 
 
Figure 8. The proportions of men and women on insulin pump therapy in Sweden 
(13) 
In 2013 FDA approved the first device that altered insulin delivery in response 
to CGM. Sensor-augmented insulin pumps can be programmed to interrupt 
insulin delivery at the certain glucose level. Medtronic MiniMed 670G 
approved by FDA as the hybrid closed-loop system that continuously tracks 
glucose levels and adapts insulin delivery (33). Users still need to adjust 
mealtime insulin delivery by themselves.   
Previous studies on CSII have identified lowered HbA1c when compared with 
MDI (129), but the effect has been modest (130). Fewer severe hypoglycemic 
events are associated with CSII, and it is suggested that CSII is associated with 
quality of life benefits (131, 132). However, treatment with CSII is more 
expensive than treatment with MDI. Available studies show that CSII is 
costeffective in comparison to multiple injections in T1D patients with poor 
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glycemic control and/or hypoglycemia on MDI (133). Selecting patients who 
would most benefit from insulin pump therapy is still challenging (127).  
 
Figure 9. Eligibility for insulin pump therapy (127, 134) 
2.3.3 CONTINUOUS GLUCOSE MONITORING DEVICES 
Many studies have reported that increased frequency of self-blood glucose 
monitoring improves overall glycemic control (133, 135).  However, even 
frequent self-blood glucose monitoring give information about the glycemia at 
the certain point of time, without providing information on trend. Continuous 
glucose monitoring devices solve these difficulties and provide valuable 
information on direction, duration of glycemic oscillations, frequency 
continuously around the clock and with no need to pierce the skin multiple 
times a day. Several technologies and algorithms have been developed and 
introduced to the market. Currently, available CGM devices have a wire-based 
enzyme-tipped electrode (sensor) (136).   It is placed in the subcutaneous 
tissue, usually on the abdomen (the forearm or gluteal area are suitable) and 
transmits the signal wirelessly to a monitor. The CGM device needs to be 
calibrated according to the manufacturer's recommendations against capillary 
blood glucose values. Every time the sensor measures glucose levels in the 
interstitial fluid, the device converts it into the estimate of blood glucose and 
shows it on a display. CGM provides early alarms for hypoglycemia or 
hyperglycemia and even information on rapidly changing glycemia (as a 
symbol on display) (137). Sensors, depending on manufacturer, are 
recommended to use for 5, 6 or 7 days and need to be changed after worth. 
Technological as well as physiological (for example, rapidly changing blood 
glucose values) issues challenge the accuracy of CGM devices.  
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Figure 10. Glucose measurement with CGM and SMBG 
 
The accuracy of CGM devices has improved over time (136). Calibration need 
has also been reduced to once per day (138). The most precise devices have 
overall mean absolute relative difference (MARD) of approximately 10% 
(1387) which is considered sufficient for making a clinical decision without 
performing a confirmatory capillary blood glucose measurement (140, 141).  
Sensors of the older generation are still used in the clinical practice. Thus, 
clinically significant variation in CGM accuracy persists.  
Randomized trials have demonstrated the benefit of CGM on glycemic control 
(142-144) and reduced time spent in hypoglycemia (145) which supports the 
recommendation to use CGM in patients with unawareness or frequent 
hypoglycemia with both CSII and MDI (144, 146). 
2.3.4 FLASH GLUCOSE MONITORING (FGM) 
During recent years Flash Glucose Monitoring (FGM) has also become a 
treatment option. An FGM system was introduced in 2014 and approved in 
Europe (144).  It consists of a sensor (inserted on the patient's forearm) and 
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reader de-vice (gets information on the actual glucose value and the 8-hour 
glucose trend). FGM is factory calibrated and does not need capillary blood 
glucose to calibrate it on a daily basis. Unlike the CGM, FGM cannot warn the 
patient of glucose oscillations, hypoglycemia or hyperglycemia. Studies show 
that overall FGM accuracy is comparable to that in CGM devices (147, 148) 
and provide evidence that FGM reduces time spent in hypoglycemia by 38% 
(149). 
 
Studies show that up to 30% of all persons with diabetes are not strictly fol-
lowing treatment recommendations provided by their diabetes-care 
provider. Persons with type 1 diabetes report different reasons for this. 
Technical devices, for example, insulin pump, continuous glucose 
monitoring, flash glucose monitoring or combination of these, may improve 
adherence to diabetes treatment. Selecting patients who would most benefit 
from different technical devices is still challenging. 
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3 AIM 
The overall aim of this thesis is to deepen the understanding of type 1 diabetes, 
particularly effects of different types of modern diabetes treatment and how 
the basic diabetes treatment is functioning today. It is essential to identify fields 
that need to be improved to reach better glycaemic control. Another aim is to 
analyze if the overall major cardiovascular events risk level as well as in the 
subpopulation of patients with well-managed type 1 diabetes (good glycaemic 
control and no renal complications) is approaching what we see in the general 
population.  
Aims and objectives of the sub-studies 
Study I 
To evaluate to what extent the guidelines for the regular Glycosylated 
Haemoglobin (HbA1c) monitoring of type 1 diabetes are followed in clinical 
practice in Sweden. 
Study II 
To evaluate the accuracy, of two commercial continuous glucose monitoring 
systems (Enlite (Medtronic MiniMed, Inc., Northridge, CA) and Dexcom (San 
Diego, CA) G4 PLATINUM) in ambulatory patients with type 1 diabetes and 
their satisfaction with devices. 
Study III 
To study whether the relative effect of insulin pump therapy on HbA1c differs 
with respect to baseline characteristics. 
Study IV 
To study the overall excess risk of major coronary events (acute myocardial 
infarction (AMI) or death from coronary heart disease (CHD)) among patients 
with type 1 diabetes and how it is related with respect to glycaemic control and 
severity of renal complications. 
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4 PATIENTS AND METHODS 
Quantitative designs have been used in this thesis. The summary information 
of data collection years, design, participants, data collection and analyses in 
the studies are presented in table 2. 
 
Table 2. Overview of data collection years, design, participants, data 
collection and analyses in the performed studies.   
Study Data 
collection 
(year) 
Design Participants Data collection Analyses 
I 1 January 
2005 to 31 
December 
2009 
Multicenter 
retrospective 
observational 
cohort study 
based on 
electronic 
medical records 
database 
5989 T1D 
patients 
Frequency of 
HbA1c 
measurements 
and other 
patient 
characteristics 
Mean 
number of 
HbA1c 
checks 
Generalized 
Estimating 
Equations 
(GEE) 
models 
Stepwise 
logistic 
regression 
II 2013 A non-
randomized, 
non-blinded, 6-
day clinical 
study, 
simultaneous 
use of both 
tested sensors 
46 CGM 
naive T1D 
patients  
CGM, venous 
and capillary 
blood glucose, 
Questionnaire 
Wilcoxon 
signed-rank 
test 
Sign test 
Spearman 
correlation 
coefficient  
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III 2000 to 
September 
2009 
Multicenter 
retrospective 
observational 
cohort study 
based on 
electronic 
medical records 
database 
272 T1D 
patients on 
CSII and 2437 
T1D patients 
on MDI 
HbA1c 
measurements 
and other 
patient 
characteristics 
Fisher’s 
exact test 
Student's t-
test, MIXED 
procedure 
IV 1 January 
1998 to 31 
December 
2011 
Nationwide 
population-
based 
observational 
cohort study 
33170 T1D 
patients and 
164698 
matched 
controls from 
the general 
population 
Data from NDR 
and other 
registries 
Rates of 
events per 
1,000 patient 
years 
Cox 
regression 
 
The study cohort for study I and III included patients with type 1 diabetes from 
10 hospital-based diabetes clinics for adult outpatients (18 years or older) in 
Sweden (Figure 11). The study I included all persons with type 1 diabetes, 
registered in the medical patient record system Diab-Base from 1 January 2005 
to 31 December 2009 (n=5989). Study III included persons with type 1 
diabetes with diabetes duration of more than one year and CSII treatment for 
at least 5.5 years. Other inclusion criteria were: available HbA1c values within 
six months before the start of CSII and at five years ± 6 months (n=272). 82% 
of all patients on CSII treatment for at least 5.5 years were included. Patients 
with intermittent use of CSII were excluded. The control group consisted of 
persons with T1D treated with MDI (n= 2437). The same criteria (diabetes 
duration and available HbA1c values) were also applied to the persons 
included in the control group. Controls were matched to each patient from the 
CSII group with respect to CSII start date.  As in the study I data for study III 
were obtained from the medical patient record system Diab-Base. 
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Figure 11. Orange and light green colors indicate counties from where we included 
persons with T1D to study I and III. Majority of persons with T1D included in study I 
and III live in the Västra Götaland county (orange). 
Study II was performed at the NU-Hospital Group in the western part of 
Sweden. 46 adult (age 18 or older and <75 years) persons with type 1 diabetes 
were included. Current pregnancy, cognitive dysfunction and other conditions 
making CGM use difficult, continuous use of paracetamol, or current use of a 
CGM sensor were considered as exclusion criteria (for more information, see 
figure 12). All subjects gave informed consent, an internal review board ethic 
approved the study. 
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Figure 12. Study II. Exclusion criteria 
 
Study IV was a nationwide population-based observational cohort study. Study 
subjects (T1D patients without previous myocardial infarction, n=33170) were 
selected from the National Diabetes Registry (NDR) using the following 
epidemiologic criteria:  
1. Treatment with insulin 
2. diagnosis of T1D at ≤30 years of age. 
164698 controls matched on age, sex and county were randomly selected from 
the Swedish Population Register. All T1D patients with previous AMI and 
their matched controls as well as controls with previous AMI were excluded 
(figure 13). 
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Figure 13. Flowchart of patient inclusion study IV  
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4.1 DATA SOURCE 
Study I, III 
Data for the study I and III were obtained from a medical patient record system, 
Diab-Base (Journalia AB, Östra Ämtervik, Sweden). Diab-Base started in 
1994, and since approximately the year 2000 it was used at ten hospital-based 
diabe-tes clinics for adult outpatients (18 years or older) in Sweden (13). 
Clinical information (risk factors, treatments, including information on the date 
of CSII initiation, and complications) was recorded to Diab-base at regular 
clinic visits. Recorded information, such as HbA1c, blood pressure, blood 
lipids, body mass index (BMI), type of diabetes, and insulin dose can be 
retrieved electronically. 
 
Study II 
46 adult ambulatory patients with type 1 diabetes at the NU-hospital group 
were included in the study. Each enrolled study patient had two subcutaneous 
CGM sensor inserted during a 4-6 days period. Each sensor produced a 
maximum of 1,440 tissue fluid glucose measurements per 24 hours. Each study 
patients sampled capillary blood and measured (using HemoCue glucometer) 
the concentration of glucose 6 to 10 times per day and registered in the written 
diary. Information on activities, meals, and taken insulin doses was registered 
by the patients in the written diary. Each patient had three visits to the clinical 
research unit, during the second and third visits seven venous blood samples 
and simultaneous capillary blood samples were taken.   
 
Study IV 
The study participants (persons with type 1 diabetes) were identified using the 
epidemiological criteria (type 1 diabetes diagnosed before the age of 30 and 
that the person was treated with insulin) (15). Clinical data were collected from 
the NDR.  NDR includes information on risk factors, diabetic complications 
with the year of diabetes onset, and medications in adult patients. Matched 
controls were randomly selected from the Swedish Population Register which 
is administered by the Swedish Tax Agency. Information on comorbidities and 
cause-specific mortality were retrieved by linking personal identifying 
numbers from persons with T1D and controls to the Swedish Inpatient and 
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cause of death registries. Information on prescribed drugs was retrieved by 
linking personal identifying numbers to the Prescribed Drug Registry. 
Education and country of birth were retrieved from the Longitudinal 
Integration database for health insurance and labor market studies (LISA by 
Swedish acronym).  
The Swedish Inpatient registry (IPR) includes information on hospitalization 
and outpatient visits (not visits to the primary care), hospital discharge 
diagnosis according to International Classification of Disorders (ICD). 
Currently, more than 99% of all discharges are registered in this register. The 
positive predictive value (correct diagnosis in IPR, when only primary 
diagnoses were considered) of the MI has been demonstrated to be 95-98% 
(148).  
The Cause of Death Registry (CDR) contains information on date, the location 
of death, ICD code and main cause of death. All death cases are registered in 
CDR. External validation has shown correct diagnosis in 87% for ischemic 
heart disease. 
The Prescribed Drug Registry (PDR) contains information on drug 
prescriptions dispensed at pharmacies since July 2005. Inpatient prescriptions 
and over-the-counter medications are not registered in PDR. 
The Longitudinal Integration database for health insurance and labor market 
studies (LISA) started in 1990. The LISA register includes all individuals from 
16 years of age that were registered in Sweden as of December 31 for each 
year and included several demographic, socioeconomic and occupational 
factors which are updated annually. 
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4.2 PROCEDURES 
Study I 
Assessment of the frequency of HbA1c measurements for all patients: 
• by the calendar year, 
• diabetes outpatient clinic (care unit),  
• also, the period when patients achieved 
a. good (HbA1c ≤ 52 mmol/mol (7.0%) and  
b. inadequate glycemic control (HbA1c> 53 mmol/mol). 
Potential predictors for receiving a subsequent HbA1c check within 4 and 7 
months after an HbA1c value >53 mmol/mol such as age, sex, type of insulin 
delivery (MDII or CSII), diabetes duration, HbA1c level, weight, BMI, insulin 
dose (U/kg), and care unit were examined. According to the guidelines, HbA1c 
should be tested at least every six months in persons who have good glycaemic 
control and every three months in persons who have inadequate glycemic 
control. In real life it may be challenging to retest HbA1c precisely after 3 or 
6 months, so we chose to extend the periods to 4 and seven months 
respectively. 
Study II 
Adult (age 18 or older and <75 years), CGM naive patients with type 1 diabetes 
were included in the study. Each study participant was the own control due to 
simultaneous use of two different sensors. Each patient made three visits to the 
clinical research unit (CRU). At the first visit informed consent was taken and 
a complete medical history was obtained. Study personnel inserted two CGM 
sensors subcutaneously and educated the participant on how to use the CGMs. 
Subjects were advised to manage their diabetes using the HemoCue SMBG 
meter (standard glucometer in the Swedish healthcare system) and their usual 
insulin delivery method. The CGM sensors were calibrated according to each 
manufacturer's instructions using a capillary blood sample analyzed with the 
HemoCue analyzer. Subjects were informed not to perform clinical decisions 
based on the CGM meter and to double check the glucose level with HemoCue 
SMBG if CGM meter was alarming for low glucose. 
The following variables were recorded at the first visit:  
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age, sex, diabetes diagnosis, data on diabetes complications and comorbidities, 
insulin delivery and dose, other medications. Persons´ height, weight, waist 
circumference, abdominal sagittal diameter height, systolic and diastolic blood 
pressure were measured during the visit to the study centre. Every participant 
was asked about an average number of subjective hypoglycaemias per month 
during the last year, smoking habits and duration, alcohol intake.  
At visits 2 and 3, each patient was admitted to the CRU to obtain seven venous 
blood samples on Days 1–3 and 4–6, with an interval of at least 15min. An 
intravenous catheter was inserted to facilitate blood sample acquisition. 
Capillary blood was sampled from the fingertip using a lancet at the first and 
last venous sample and an intermediate sample. 
The sensor insertion sites were observed to detect bleeding, inflammation, and 
infection of the skin or subcutaneous tissue. 
Predefined endpoints were: 
Primary endpoint 
The difference in mean absolute relative difference (MARD) between Enlite 
(Medtronic MiniMed, Inc., Northridge, CA) and Dexcom (San Diego, CA) G4 
PLATINUM. 
Secondary endpoints 
The accuracy of Enlite (Medtronic MiniMed, Inc., Northridge, CA) and Dex-
com (San Diego, CA) G4 PLATINUM sensors at: 
• day 1-3 
• day 4-6 
• hypoglycemia (<4 mmol/L) 
• euglycemia (4-10 mmol/L) 
• hyperglycemia (>14 mmol/L) 
Endpoints were analyzed using capillary glucose values as the reference and 
investigating MARD and MAD (mean absolute difference), absolute 
correlation coefficient, median absolute relative difference, median absolute 
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difference. All statistical analyses were described in the statistical analysis plan 
(SAP). 
During the last visit to the CRU, all patients filled the questionnaire with 13 
identically formulated evaluative statements for Enlite and Dexcom G4.  
Participants could agree or disagree according to visual analog scale (VAS). 
The patient could also provide free-form text comments on their experience. 
Study III 
Evaluation of the relative effect of CSII compared with MDI on the HbA1c 
lev-el at 1, 2, and 5 years with respect to baseline characteristics. Age, sex, 
diabetes duration, BMI, insulin dose (U/kg/day), baseline HbA1c level, and 
care unit were examined as possible predictors for greater or lower effect of 
CSII com-pared with MDI on HbA1c*. 
*HbA1c values were converted to the National Glycohaemoglobin 
Standardization Program and International Federation for Clinical Chemistry 
standards. 
Study IV 
Estimation of the rates of major coronary events for the following age groups 
18-34, 35-49, 50-64 and 65 years or greater and by gender in the T1D 
population and controls was performed. Cox regression analysis adjusted for 
age and sex and in addition also for comorbidities and level of education was 
performed to further evaluate the overall excess risk for coronary events in 
persons with T1D compared to controls. In a next step evaluation of the 
influence of glycaemic control and renal complications on the risk of AMI and 
CHD in patients versus controls was performed. Updated mean HbA1c* value, 
i.e., the mean level of HbA1c until a certain time point, was used to categorize 
persons with T1D by glycaemic control. Renal complications were categorized 
into normo-, micro- and macroalbuminuria and stage 5 chronic kidney disease 
and into stage 1 (eGFR ≥ 90 ml/min), stage 2 (eGFR 60-89 ml/min), stage 3 
(eGFR 30-59 ml/min), stage 4 (eGFR 15-29 ml/min) and stage 5 chronic 
kidney disease (renal dialysis, renal transplantation, or eGFR <15 ml/min). 
*International Federation of Clinical Chemistry (IFCC) standard 
measurement units mmol/mol used in the study. Dual reporting according to 
the National Glycohaemoglobin Standardization Program was also 
performed. 
Viktorija Matuleviciene Anängen 
39 
4.3 STATISTICAL ANALYSIS 
The main statistical methods are described in detail in the respective studies. 
Statistical methods are summarized in Table 3. 
 
Table 3. The main statistical methods 
Study Point of interest Used statistical method 
All Demographic characteristics Continuous variables: mean with SD for 
normally distributed variables, median 
(for skewed distributed variables) with 
min and max values, and within-
individual SD as applicable when 
repeated measures are available  
Categorical variables: number with 
percentages. 
 Unless otherwise specified, a 
p-value below 0.05 was considered 
statistically significant 
I Frequency of HbA1c 
measurements 
-Mean number of HbA1c checks per year 
for each individual patient 
-Mean number of HbA1c checks for 
entire cohort calculated as the mean 
number of annual means 
-Mean number of HbA1c checks during 
the periods of optimal and inadequate 
glycemic control. 
The probability of HbA1c 
check within 4 and 7 months 
after HbA1c measurement >52 
mmol/mol 
Generalized Estimating Equations (GEE) 
models. This method was chosen to 
analyze binary outcome that comes from 
repeated measures for same individuals. 
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Independent predictors of 
HbA1c check within 4 and 7 
months after HbA1c 
measurement >52 mmol/mol 
Stepwise logistic regression: multiple 
regression performed several times, each 
time including the strongest and 
significant correlated variable. 
GEE models for selected variables 
performed. OR, CI and p-value were 
calculated for each variable. 
II Comparison of two CGM 
systems 
Mean absolute relative difference 
(MARD)- for the primary measure of 
accuracy, which is the standard method 
for evaluation of CGM. 
Mean absolute difference (MAD) 
Absolute Pearson correlation coefficient 
Median absolute relative difference 
(MedARD) 
Median absolute difference (MedAD) 
To compare two sets of scores that come 
from the same participants Wilcoxon 
signed-rank test was used for continuous 
variables. 
To compare categorical differences 
(differences between pairs of 
observations) between CGM systems, the 
Sign test was used. 
Association between capillary 
and venous blood glucose 
values 
Spearman correlation coefficient and 
associated p-values. 
III Comparison between CSII and 
MDI groups 
Fisher’s exact test for dichotomous 
variables and Student’s t test for 
continuous variables 
Evaluation of the effect size 
for interaction variables 
between each baseline 
variable (age, sex, diabetes 
duration, BMI, insulin dose, 
HbA1c level at the baseline, 
care unit) 
Analysis of covariance 
Interaction was considered statistically 
significant for p<0.10 
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IV Rates of coronary events, 
compared to the matched 
controls 
Poisson CI, expressed in cases per 1000 
patient years 
Expected duration of time 
until event (major coronary 
event or death due to CHD) 
studied for different categories 
of HbA1c, albuminuria and 
eGFR 
Cox regression, adjusted for following 
variables: 
Model 1 – time-updated age and sex 
Model 2 – model 1 + diabetes duration 
categories at baseline 
Model 3 – model 2 + education category, 
birth in Sweden, comorbidities prior the 
baseline 
Overall and stratified by gender. 
 
Separate Cox regression models were 
used to evaluate the risk of major 
coronary events and death from CHD 
associated with glycemic control or/and 
kidney impairment or/and albuminuria 
during follow-up period. These variables 
were categorized into blocks (please see 
paper IV).  
All Cox models were tested for the 
proportional hazard assumption and 
satisfied this assumption. 
Effect per 10 mmol/mol higher 
updated mean HbA1c 
Cox regression within diabetes 
population. 
Influence of time <2005 vs 
≥2005 
Cox regression, with baseline 
comorbidities updated for time period 
>=2005. 
Effect of HbA1c in the lowest 
category, ≤ 52 mmol/mol 
Sensitivity analysis, by using Cox 
regression 
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4.4 ETHICAL CONSIDERATIONS 
 
Study I, III, IV 
Ethics approval was obtained for the studies I, III and IV from the ethical 
committee at the University of Gothenburg, Gothenburg, Sweden. No invasive 
procedures have been performed in the study I, III and IV.  
 
Study II 
The study was approved by the internal review board at the NU-Hospital 
organization.  
Each subject was assigned an anonymous ID number used to identify the 
subject in all study records. All study subjects were asked to sign an informed 
consent form (ICF) before initiating any study procedures. The study was 
conducted in strict accordance with the protocol. 
All study participants were informed orally and in written about the purpose of 
the study, voluntary participation and confidentiality. 
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5 RESULTS 
 
5.1.1 STUDY I  
A Retrospective Study in 5989 Patients with Type 1 Diabetes in 10 Outpatient 
Diabetes Clinics in Sweden of the Frequency of Measuring HbA1c in Clinical 
Practice  
Main findings:  
5989 patients with type 1 diabetes from 10 outpatient diabetes clinics in 
Sweden were included in the study.  
Table 4. Patient characteristics at first visit during years 2005-2009 in Diab-
Base in total and in relation to the number of mean number of annual HbA1c 
measurements performed during the same period. (Reproduced with permission 
from the publisher) 
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From the chart below, we can see that during the periods with HbA1c >52 
mmol/mol, persons with T1D had 1.83 annual HbA1c measurements (the 
follow-up period from 1 January 2005 to 31 December 2009). See Figure 14. 
Figure 14. The frequency of HbA1c measurements during the time periods with 
HbA1c > 52 mmol/mol 
As shown in figure 15, only in 35.4% of cases the next HbA1c measurement 
following an HbA1c >52 mmol/mol was performed within 4 months. 
Figure 15. Subsequent assessment of HbA1c within 4 months following an HbA1c 
value >52 mmol/mol 
Patients treated with CSII compared to MDI, younger individuals compared to 
older, those with shorter diabetes duration, females, patients with higher 
HbA1c and those who were followed-up in the certain care units had a 
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significantly higher probability of having the subsequent HbA1c measurement 
within 4 months (Table 5, article 1). 
Table 5. Probability of having a subsequent HbA1c measurement within 4 
months after an HbA1c >52 mmol/mol, study I (Reproduced with permission 
from the publisher) 
 Univariable Multivariable 
Variable OR 
(95% CI) 
p-value OR 
(95% CI) 
p-value 
Sex (1=male, 2= female) 1.20 
(1.12-1.28) 
<0.001 1.12 
(1.05-1.21) 
0.0017 
Current age (by 10 years) 0.87 
(0.85-0.89) 
<0.001 0.94 
(0.92-0.96) 
<0.001 
Diabetes duration (by 10 years) 0.89 
(0.87-0.91) 
<0.001 0.93 
(0.91-0.96) 
<0.001 
CSII (0=No, 1=Yes) 1.65 
(1.54-1.78) 
<0.001 1.57 
(1.46-1.69) 
<0.001 
Current calendar year 1.13 
(1.11-1.15) 
<0.001 1.14 
(1.12-1.17) 
<0.001 
Current HbA1c  1.38 
(1.34-1.41) 
<0.001 1.37 
(1.34-1.41) 
<0.001 
 
As it can be seen from the table above, T1D patients with CSII compared to 
patients with MDI treatment had approximately 50% higher probability of 
having a novel HbA1c check within the recommended time interval. 
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5.1.2 STUDY II 
A Clinical Trial of the Accuracy and Treatment Experience of the Dexcom G4 
Sensor (Dexcom G4 System) and Enlite Sensor (Guardian REAL-Time 
System) Tested Simultaneously in Ambulatory Patients with Type 1 Diabetes 
Main findings: 
46 persons with T1D were enrolled to the clinical study. Those, who had 
recorded at least 10 capillary glucose values matched at a maximum deviation 
of 5 minutes from the CGM values, were included in the intention-to-treat 
analysis (n=38). The table below illustrates some of the main characteristics of 
the intention-to-treat population (table 6). 
Table 6. Demographic characteristics (study II) 
Variable Intention to treat population (n=38) 
Age (years) 50.0 (14.3) 
50.1 (20.8,73.6) 
Sex 
-male 
-female 
 
-25 (65.8%) 
-13 (34.2%) 
Diabetes duration (years) 22.9 (16.0) 
18.0 (1.0; 57.0) 
Insulin delivery 
-CSII 
-MDI 
 
-10 (26.3%) 
-28 (73.7%) 
HbA1c (IFCC, mmol/mol) 58.9 (10.5) 
59.0 (34.0; 77.0) 
For continuous variables data are mean (SD)/median (minimum, maximum)/n 
 
The primary endpoint was the difference in MARD between the two systems 
over the whole study period. As the table 7 shows, there was a significant 
difference in MARD between the Dexcom G4 and Enlite during the entire 
study period (primary endpoint), during days 1-3 and days 4-6, as well as 
during the periods when glucose values were below 4.0 mmol/L and 4.0-10.0 
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mmol/L (secondary pre-defined endpoints). The Dexcom G4 sensor was hence 
more accurate during the entire study period and during hypoglycemia and 
normoglycemia. No significant difference in the accuracy was found at very 
high glucose levels (>14mmol/L), MARD: 12.1% for Dexcom G4 and 13.9% 
for Enlite (P=0.24). 
By the end of the study period, all study participants completed and returned 
the questionnaire. The questionnaire required respondents to give information 
on their satisfaction, easiness and other experiences with CGM systems. We 
used a visual analog scale with the lowest value of 0, indicating "not true at 
all" and the highest value of 100, indicating "completely true.” As it can be 
seen from the figure 16, participants felt more positively about the Dexcom G4 
system compared to the Enlite system. This was observed in 12 out of 13 
questions. Study participants were also asked to give a free-text comment on 
their experience with Dexcom G4 and Enlite systems. Some of the participants 
pointed signal disturbances (e.g., low signal) as a very important issue. "Even 
if sensor accuracy increased, I would not feel safe using this system if a low 
sensor signal became a frequent problem", - one of the study participants 
commented. 
 
 
 
Figure 16. Some of the predefined user experience questions 
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Table 7. Primary and secondary endpoints of accuracy evaluations, study II. 
Reproduced with permission from the publisher. 
 Dexcom 
G4 
Enlite Sets of 
measurements 
p-value 
MARD (all data) 13.87 
(5.24) 
12.4 (6.9; 
29.1) 
17.85 
(5.65) 
16.8 (9.3; 
30.5) 
1012 <0.0001 
MARD (Capillary 
glucose levels <4.0 
mmol/L) 
20.04 
(15.13) 
17.0 (2.6; 
61.7) 
n=28 
34.69 
(21.43) 
30.4 
(2.8;97.1) 
n=28 
80 0.0041 
MARD (Capillary 
glucose levels 4.0-10.0 
mmol/L) 
14.09 
(5.91) 
12.9 (5.6; 
32.1) 
n=38 
17.33 
(6.29) 
16.4 (7.8; 
36.3) 
n=38 
668 0.0008 
MARD (Capillary 
glucose levels > 14.0 
mmol/L) 
12.13 
(7.96) 
11.6 (0.3; 
31.5) 
n=25 
13.94 
(7.75) 
11.8 (2.4; 
31.1) 
n=25 
70 0.24 
MARD (day 1-3) 15.01 
(6.78) 
12.9 (5.7; 
36.7) 
n=37 
19.41 
(7.76) 
17.6 (7.0; 
38.2) 
n=37 
545 0.0027 
MARD (day 4-6) 13.57 
(6.70) 
12.8 (6.8; 
41.1) 
n=37 
15.88 
(5.22) 
15.8 (6.4; 
28.5) 
n=37 
467 0.026 
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5.1.3 STUDY III 
Predicting the Effectiveness of Insulin Pump Therapy on Glycemic Control in 
Clinical Practice: A Retrospective Study of Patients with Type 1 Diabetes from 
10 Outpatient Diabetes Clinics in Sweden over 5 years 
Main findings: 
In total, 272 CSII patients (82% of all patients having CSII over 5.5 years) and 
2437 MDI patients were included in this study to evaluate the 5-year effective-
ness of insulin pumps in Sweden. 
It can be seen from the data in table 8 that the CSII patient group had 
significantly higher baseline HbA1c levels compared to the MDI group; the 
mean HbA1c value was 68.1 mmol/mol (8.39%) vs. 64.7 mmol/mol (8.07%) 
respectively. Persons with CSII were younger, had shorter diabetes duration. 
More women than men were treated with CSII than MDI (56% vs. 43%). 
Table 8. Baseline characteristics (study III) 
Variable CSII (n=272) MDI (n=2437) P-value 
Sex 
-Male 
-Female 
 
119 (43.8%) 
153 (56.3%) 
 
1391 (57.1%) 
1046 (42.9%) 
 
<0.001 
Age (years) 38.6 (11.3) 
n=267 
45.6 (14.4) 
n=2437 
<0.001 
HbA1c (IFCC, mmol/mol) 68.1 (14.2) 
n=272 
64.7 (13.9) 
n=2437 
<0.001 
Diabetes duration (months) 15.1 (11.2) 
n=272 
20,1 (13.2) 
n=2437 
<0.001 
 
To determine the effect of CSII treatment compared to MDI from baseline to 
5 years, the predictive analysis of change in HbA1c over the time was 
performed. Our result shows that the higher the baseline HbA1c level, the 
greater the decrease in HbA1c. As shown in figure 17, changes in HbA1c levels 
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were observed in both the CSII and MDI groups. The decrease in HbA1c at 5 
years for patients, who had HbA1c >75 mmol/mol and BMI of 25 kg/m2 and 
were treated with CSII, was 7.5 mmol/mol (≈0.75%) compared to 5 mmol/mol 
(≈0.5%) for patients treated with MDI. Patients who had HbA1c >75 
mmol/mol at baseline, had the most prominent effect at 5 years with an HbA1c 
decrease of 2.5 mmol/mol (≈0.25%) compared to the MDI group. Significant 
interactions between CSII treatment and baseline HbA1c and BMI were 
apparent. The lower baseline BMI, the more significant reduction of HbA1c at 
the end of the follow-up period (Figure 17). No significant interactions 
between age, sex, diabetes duration, insulin dose and baseline HbA1c could be 
detected. 
 
Figure 17. Least square means for change in HbA1c (NGSP, in %) from baseline to 5 
years in patents on CSII versus MDI (no CSII), presented for selected baseline 
HbA1c and BMI values. Reproduced with permission from the publisher 
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5.1.4 STUDY IV 
Glycemic control and Excess Risk of Major Coronary Events in Persons with 
Type 1 Diabetes 
Main findings: 
In total, 33 170 persons with T1D and 164 698 controls were included in the 
analysis. In the study both groups were comparable with respect to mean age 
(35.3 and 35.1 years) and sex (proportion of women 45.3% and 45.1%). In 
persons with T1D, mean HbA1c was 65.7 mmol/mol and mean diabetes 
duration 20.0 years. The median follow-up time for T1D patients and controls 
were 8.3 years and 8.9 years, respectively. During this period 4.5% of T1D 
patients and 1.2% of controls suffered AMI or died from CHD.  
The excess risk of coronary events for persons with T1D compared to controls 
decreased over time with an adjusted HR of 3.63 (95% CI 3.33-3.95) for 
calendar years ≥2005 and an HR of 4.80 (95% CI 4.26-5.42) for calendar years 
<2005. 
Figure 18. AMI or CHD deaths per 1000 patient years by sex 
Type 1 diabetes in adults: modern treatment and risk of major coronary events 
52 
Interestingly, during the follow-up time, men and women with T1D had similar 
event rates. In controls, much lower event rates for women were displayed 
(figure 18), which matches results observed in earlier studies. 
The relative risks for AMI or CHD events expressed in HR were higher at 
younger age (4.65 and 19.15 for 18-49 years of age men and women, 
respectively vs. 2.73 and 5.21 for 65+ years of age men and women, 
respectively). The relative risk was also higher for women compared to men, 
at poor glycemic control and in relation to severity of renal complications. The 
HRs for men and women with good glycemic control and normoalbuminuria 
were 1.3 and 3.16, respectively. HRs were persistently higher for women with 
higher HbA1c levels and higher levels of albuminuria and increased also with 
lower estimated glomerular filtration rate, calculated using the MDRD 
equation. Calculations made using the CKD-EPI equation did not change the 
results. 
Figure 19. Risk of coronary events among persons with T1D in relation to glycemic 
control and renal complications compared to matched controls 
We also evaluated the relationship between 1% (≈10 mmol/mol) increase in 
updated mean HbA1c and risk of coronary events within the group of persons 
with type 1 diabetes. The HR:s for coronary events in relation to 1% (≈10 
mmol/mol) higher HbA1c adjusted for age, were 1.33 (95% CI 1.26-1.40) in 
men and 1.41 (95% CI 1.34-1.49) in women, respectively. 
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6 DISCUSSION 
 
6.1.1 GENERAL DISCUSSION 
Type 1 diabetes is usually diagnosed at childhood or early adulthood (21). 
Thus, persons with type 1 diabetes are exposed to diabetes related risk factors 
during a long period of time. Evidence shows that diabetic complications can 
efficiently be reduced by better glycaemic control (10, 11, 64). Despite this, 
the gap between the scientific evidence and clinical practice is still big. 
Currently, just approximately 20% of all adult diabetes patients in Sweden 
achieve good glycemic control (HbA1c ≤52 mmol/mol) (13.). Unfortunately, 
at least an equal number of T1D patients have very poor glycemic control 
(HbA1c > 70 mmol/mol). The present thesis is focused on persons with type 1 
diabetes regarding optimising diabetes care including evaluations of HbA1c 
testing, CGM therapy and insulin pump treatment.  Examining cardiovascular 
outcomes in persons with type 1 diabetes was another issue of high priority. 
 
6.1.2 REGISTRIES AND RECORD-BASED DATABASES 
Studies investigating the same group of individuals over a long period of time 
in clinical practice are of potential great importance in research (83). A medical 
record based database (Diab-base) was used to study persons with type 1 
diabetes from clinical practice regarding frequencies of HbA1c-testing and 
effect of insulin pump use. Appropriate analyses of databases potentially 
facilitate an understanding of T1D care and allow to identify factors which 
might be useful in order to slow or reverse outcomes of interest. The database 
comprised approximately 7000 persons with type 1 diabetes from 10 different 
diabetes care units. Results should likely be representative for healthcare of 
type 1 diabetes patients in Sweden in general.  
DCCT and EDIC were of paramount importance. Findings from these and 
landmark trials of the prevention of cardiovascular disease were implemented 
clinically (159). NDR, one of the largest databases of its kind, gave us a 
possibility to study a nationwide T1D population (epidemiological cohort) and 
evaluate the effects of implemented treatment on the incidence of the outcomes 
of interest (major coronary events). 
A registry is "an organized system that uses observational study methods to 
collect uniform data (clinical and other) to evaluate specified outcomes for a 
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population defined by a particular disease, condition or exposure, and that 
serves one or more predetermined scientific, clinical, or policy purposes" 
(154). Sweden has established tradition on national registries, counting more 
than 100 of those (161, 162). Government-administrated health registries allow 
to follow the defined group of patients of interest through their life and get 
valuable information on diagnosis, outcomes, prescribed medications, death 
year and causes (162). Research data delivered to the research team, as rule is 
anonymized to as great extent as possible, by e.g. not including the personal 
identification number. Unfortunately, registers generally only have the 
possibility to include a limited number of variables and hence information, that 
may have impact on a certain outcome may not be available. Further it should 
be noted that the findings from retrospective registry based studies should be 
interpreted with caution regarding interpretations of causality between risk 
factors and treatments in relation to outcomes. 
 
6.1.3 HBA1C TESTING 
Results from a multicenter study examining repeat HbA1c checks in nearly 
80000 persons with diabetes (both T1D and T2D) found that HbA1c testing 
frequency is associated with HbA1c changes over time (47). HbA1c reduction 
was associated with testing HbA1c every third month and in contrast HbA1c 
checks once per year were associated with increasing HbA1c values. In this 
thesis we show that persons with T1D in Sweden did not even receive two such 
visits per year on average during the first decade of the 21st century. The care 
differs between diabetes care units both regarding the mean number of annual 
HbA1c checks and even in change in HbA1c-levels over time. Little was found 
in the literature on the question of the adherence to the HbA1c testing 
frequency in patients with T1D. Earlier studies have not analysed the 
frequency of HbA1c measurements in T1D, but focused on T2D or included 
persons with both type 1 and type 2 diabetes. Results of our study agree with 
the findings of previous studies reporting non-adherence to the guidelines with 
respect to HbA1c testing frequency (47-52). It seems possible that these results 
could be explained by a general lack of resources, mainly too few nurses 
working at diabetes care units. Diabetes nurses are seen as the backbone of 
diabetes care and patient education. Another possible explanation is that the 
number of annual HbA1c checks has not been seen as a factor in evaluating 
the quality of diabetes care. A clinically important finding in our study was 
that persons with insulin pump treatment got a more extensive care than 
patients with MDI. Persons with CSII had approximately 50% greater 
likelihood to get a subsequent HbA1c check within the recommended time 
range compared to persons on MDI. A possible explanation for this result is 
Viktorija Matuleviciene Anängen 
55 
that patients on CSII probably have more contact with healthcare providers due 
to the need of technical support and possible complications with the CSII 
therapy. Another possible explanation is that patients treated with CSII may be 
more interested in their diabetes care than patients treated with MDI and 
thereby more motivated and eager to receive clinical visits. On the other hand, 
it seems inappropriate that patients with MDI receive less diabetes care and 
this group of patients should get more attention from their health care 
providers. 
Previous studies reported the association between increased SMBG and 
improved overall glycemic control (133, 135). On the other hand, a recent 
Swedish study shows that less than 50% of T1D patients follow guidelines to 
check blood glucose levels at least four times per day (151). Non-adherence to 
health care providers´ recommendations seems to be common and challenges 
the overall goal to achieve HbA1c targets according to the guidelines.  
 
6.1.4 CONTINUOUS GLUCOSE MONITORING 
DCCT study participants in the intensive management group experienced 
hypoglycaemia 2-3 times more often compared to the conventional treatment 
arm (163). Risk of hypoglycaemia is still challenging both persons with type 1 
diabetes and the health care systems (117, 133, 145). One of the possible 
technical solutions is continuous glucose monitoring. Several technologies and 
algorithms have been developed and introduced to the market, not always the 
same in different countries (137-146). Diabetes centres often base the selection 
of CGM devices on their local experience and decisions. Clinical trials 
performed before our study have shown different findings on CGM accuracy. 
Possible explanation of that may be the use of different generation of sensors, 
different types of reference methods and small datasets (143). To our 
knowledge, our study is the first to evaluate patient experiences with different 
CGM systems. Important to note is that in the previous studies, even though in 
real life patients perform calibrations with capillary blood glucose values, 
CGM systems were calibrated using venous blood glucose samples (152). We 
used the HemoCue system to estimate both capillary and venous glucose 
values in the clinical trial. The venous samples in our study were 0.78 mmol/L 
lower than capillary values; the relationship was very strong (correlation 
coefficient = 0.98). Thus, it may cause the systematically biased results if the 
reference method and the method used to calibrate the system is not the same, 
the reference method should be considered. By the two sensors most used 
during the years in persons with T1D, we showed that the Dexcom sensor was 
more accurate and patients showed higher treatment satisfaction. This work, 
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one of the first from the manufacturer economically independent evaluations 
also forms an essential basis for similar studies of novel sensors. 
 
6.1.5 INSULIN PUMP TREATMENT 
Patients with high HbA1c improve their HbA1c somewhat more than those 
with low to moderately high HbA1c when an insulin pump was introduced in 
clinical practice. These results are in line with data from previous studies (14, 
130). A long follow-up period (>5 years), multicentre design and large control 
group were the main strengths of our study. Results from some previous studies 
which were performed without the control group are difficult to interpret 
because of many other factors that may have impact on HbA1c levels, such as 
an implementation of new T1D treatment or care strategies (164-165). The 
length of the follow-up period is of great importance. Effects of any new 
intervention may give more significant results in the beginning due to 
increased visit frequency, more attention from the caregiver, higher motivation 
due to a novel therapy or due to patient education effort. Our study shows that 
the differences between CSII and MDI in effect on HbA1c changes decreased 
over time and at the end of the follow-up period were not that great that may 
be expected (approximately 2.5 mmol/mol in favour of CSII compared to the 
MDI group in patients with very high HbA1c >75 mmol/mol). Otherwise, 
previous studies have demonstrated that patient on CSII experience fewer 
severe hypoglycemic events, reduce variations in blood glucose concentrations 
and achieve a better quality of life (131-133). We could not identify other 
clinical variables (except the higher HbA1c levels at the baseline) that would 
predict greater change in HbA1c over the time. The decision to switch to the 
CSII treatment likely needs to be taken mainly on other parameters based on 
individual judgment of the life situation, view and motivation from the patient. 
 
6.1.6 RISK OF MAJOR CORONARY EVENTS  
The DCCT/EDIC studies have demonstrated benefits of an intensive diabetes 
therapy and more evident effect of “metabolic memory” phenomenon lasting 
years later (64, 83). Reduction of major cardiovascular risk factors in persons 
with diabetes became a focus point. In the context of improved healthcare 
guidelines, we evaluated an excess risk of AMI or death from CHD in persons 
with type 1 diabetes. This nationwide study from 1998 to 2011 shows that the 
excess risk of AMI or death from coronary events is four-fold higher compared 
with the general population in Sweden.  Another important clinically relevant 
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finding was that women had greater excess risk of AMI or CHD death at any 
age compared to men. These results match those observed in earlier studies, 
such as the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study 
and Pittsburg Epidemiology of Diabetes Complications (EDC) study in US (3). 
A systematic review from 26 studies, including 214114 persons with type 1 
diabetes shows that women have a roughly twice the excess risk of vascular 
events, compared with men (156). The exact pathophysiological mechanism of 
this is not known and needs further investigations. However, some authors 
have proposed that risk factors may have different impact on men and women, 
for example HDL (157, 158). Lower levels of HDL are considered to be an 
important factor contributing to the increased cardiovascular risk (3, 157).  Fat 
distribution patterns, coagulation, insulin resistance have also been proposed 
as the possible explanations to the lost cardiovascular protection which is 
usually associated with female sex (3, 157). Other risk factors such as 
hypertension or hypodinamia differences by gender reported stronger impact 
of them on women’s cardiovascular health (157). It may be believed that 
women with type 1 diabetes have much higher risk, compared to men. This is 
however not the case, but these associations are in principle explained by 
different risks in the general population by sex with respect to MI. In our study 
we see a very similar incidence rate of major coronary events in men and 
women with T1D. 
Earlier studies have also shown an excess risk of myocardial infarction in 
persons with type 1 diabetes compared to the general population in various 
populations (3, 156). However, to our knowledge population-based 
evaluations of the excess risk in relation to risk factor control have not been 
extensively performed. Our results show that excess risks of major coronary 
events are substantially reduced at good glycaemic control and no renal 
complications. In our study, persons who had good glycemic control and no 
renal complications had much lower HR compared to the persons with poor 
glycemic control and albuminuria and/or impaired renal function. HR in 
persons with good control, especially in men, is narrowing to that in the general 
population. The relevance of existing guidelines promoting good glycaemic 
control is clearly supported by the current findings. However, the important 
question whether targeting general goals for HbA1c is enough to reduce the 
risk of MI to that in the general population is more difficult to conclude. The 
adjusted HR in man and women with good glycaemic control and 
normoalbuminuria was 1.3 and 3.16, respectively. It is possible that persons 
with current good glycaemic control had worse glycaemic control before the 
follow-up period. Moreover, the confidence interval for HR in men is wide 
(0.9 to 1.88), so the substantial excess risk cannot be concluded or excluded in 
this group. The HR in women was 3.16 with the 95% confidence interval 
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between 2.14 to 4.65. It indicates that targeting glycemia levels is not enough 
to effectively reduce the excess risk of coronary events in women. More 
research in this field is needed. More effective treatment and cardiovascular 
prevention strategies with the focus on gender differences may be of help. 
 
6.1.7 STRENGTHS OF THE STUDIES 
Strengths of study I, III and IV are the large samples, the long length of follow-
up and measurement of clinical risk factors. The strength of the studies I and 
III is the data source, Diab-Base, providing detailed clinical information 
including all HbA1c values and date for insulin pump start. The study I was 
the largest study in T1D patients documenting adherence to the treatment 
guidelines in a real-life population.  Study III was able to estimate the effects 
of CSII on HbA1c from many care units over a long time period whereas most 
other studies in the field have substantially short follow-ups, are performed at 
a single centre or lack a control group (164-165). Another strength of study III 
is that among all patients treated with CSII over five years during the study 
period, 82% had information on HbA1c before starting CSII and at five years 
and could be included in the analyses. 
A strength of the study II is that the study was performed entirely 
independently from CGM manufacturers. Other strengths are that all endpoints 
were predefined and statistical methods were described in a signed statistical 
analysis plan (SAP) before the database was locked. Every patient was its own 
control; the same factors influenced both CGM-meters (behaviour, same range 
of glycemia, same environmental factors). It was the first study evaluating 
patient's experience of CGM and gave the opportunity to compare two different 
CGM systems. This kind of experience is not possible to obtain from clinical 
practice, since in real life patients only use one of the CGM devices. 
Strengths of the study IV include the population-based design where nearly all 
patients with type 1 diabetes in Sweden were included, and presence of 
matched controls that were randomly selected from the general population. 
Further, information of comorbidities and level of education existed for both 
persons with T1D and controls, making it possible to adjust for these variables. 
Another strength of the study is that the Swedish National Diabetes Registry 
has a good coverage regarding risk factors.   
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6.1.8 LIMITATIONS OF THE STUDIES 
Some important limitations of the studies need to be considered. Data for study 
I and III were collected from 10 outpatient diabetic clinics, most of which are 
in the same geographical region in Sweden. At the same time, more persons 
with T1D in this region have optimal glycemic control compared to all persons 
with T1D in Sweden (24.8% vs. 20%), and the quality of diabetes care in this 
region is therefore likely high (12). It may happen that results could differ in 
other parts of the country, but it is unlikely that other regions in Sweden 
perform substantially more HbA1c checks and reach the recommended goal of 
4 annual measurements. All psychosocial variables were not available for 
study I and III. It is possible that various psychosocial variables may be related 
to the probability of having HbA1c check or usage of an insulin pump and may 
be related to possibilities to come to clinical visits. Hypoglycemia is difficult 
to record properly in clinical practice for several reasons. These data were not 
available for study I, III and IV. Absence of this variable may contribute to the 
missed aspects of interpretation of results. Information of several important 
risk factors for coronary events including smoking, blood pressure and lipid 
levels were not available among controls in Study IV. Further, information of 
several life-style factors including physical activity and dietary habits were not 
available in the studies. Data on the use of cardioprotective medications were 
available only from 2005. (limitation for study IV). Another limitation in study 
IV is that it cannot be excluded that non-severe AMI may be underdiagnosed 
to some extent among controls, since persons without diabetes attend their 
health care provider less frequently compared to the diabetes population. 
Emigration is one of the possible challenges and it was not possible to get 
information on whether and when persons who emigrated, died or got AMI. 
A limitation to the study II is the short duration used to measure the treatment 
experience. Another limitation is the selection of participants: every patient 
needed to come to 3 scheduled visits at the CRU during the limited 6 days 
period. This influenced the selection of study participants due to social factors 
and may affect the representability of participants (likely more important for 
the part of the study regarding treatment satisfaction). Technological progress 
is very evolutionary, and findings obtained in the study must be interpreted 
with caution when making recommendations on what CGM device to choose 
in clinical practice today.  
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7 CONCLUSION 
Study I 
In persons with type 1 diabetes with inadequate glycaemic control, HbA1c is 
measured less than two times per year in clinical practice in Sweden compared 
to four times per year recommended in guidelines. More frequent visits could 
likely improve HbA1c levels and reduce the risk of complications. Patients 
with MDI had lower frequency of HbA1c checks compared with T1D patients 
on CSII. This patient group needs extra focus. 
Study II 
In a from the manufacturers economically independent study we found that the 
Dexcom G4 sensor was associated with both greater accuracy and treatment 
satisfaction than the Enlite sensor.  The high accuracy and treatment 
satisfaction with the DexCom system is useful information also today since it 
is still commonly used in clinical practice.  We found that independent studies 
comparing CGM systems had rarely been performed before our study. Hence, 
there is a need of studies using the same concept as in ours for evaluating novel 
sensors and CGM systems, especially since long-term comparative 
randomized trials are difficult to perform before novel sensors or CGM 
systems are developed and are so far lacking in the field. 
Study III 
Patients with high HbA1c levels have a greater probability of improved HbA1c 
after initiating pump therapy, but effects remain relatively moderate even for 
T1D patients with poor control. Healthcare needs other treatment alternatives 
in order to improve the glycemic control significantly. Insulin pump treatment 
is valuable. Thus, a certain reduction of HbA1c occurs, and according to other 
studies, it has positive impact on the quality of life and time spent in 
hypoglycemia. 
Study IV 
T1D patients had approximately four times higher risk of myocardial infarction 
compared to the general population. However, this level is lower than results 
from some other historical studies from different part of the world.  The 
absolute risk of coronary events in persons with T1D was similar for men and 
women, whereas the excess risk compared to the general population was 
greater for women than for men. A strong relationship exists between 
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glycaemic control and coronary events in persons with T1D. Excessive risk is 
much lower for patients with well-controlled diabetes and absence of kidney 
injury. Intensive cardioprotective strategies are still needed for persons with 
T1D. 
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8 FUTURE PERSPECTIVES 
The present thesis shows that health care strategies for persons with type 1 
diabetes were not optimal during the period our studies were conducted (1998- 
2014). Impaired glycaemic control was strongly associated with the risk of 
coronary events in persons with T1D and highlights the importance to focus 
on better methods to improve the glycemic control. Systematic and continuous 
efforts should be made to ensure that essential parts of diabetes care, such as 
follow up visits at the diabetes care clinics, especially for those patients who 
are on MDI treatment, are improved. It is essential that independent 
comparative studies of sensors and CGM systems are performed since we show 
here that both accuracy and treatment satisfaction can greatly differ between 
sensors and CGM systems. Such information is of use for clinicians and 
decision makers in treating persons with T1D.  Improved tools for guiding the 
choice of modern therapies including CGM and insulin pump therapy would 
be beneficial. Since the effect on HbA1c of insulin pump in clinical practice is 
modest also in persons with poor glycaemic control clinicians need to be aware 
that other treatment strategies are crucial for improving the overall glycaemic 
control in persons with T1D. 
More research is needed to estimate to what extent modifiable risk factors 
affect the progression of cardiovascular complications and how coronary 
events can be reduced in persons with T1D. Cardioprotective strategies, 
including primary and secondary prevention, need to be improved. Specific 
smoking cessation programs for persons with type 1 diabetes could be 
implemented. Continued aggressive treatment with lipid-lowering (statin) 
medication is essential, but further investigations particularly for type 1 
diabetes patients are needed. It is most likely that a similar preventive effect 
exists for this patient group since it has been shown in many other populations. 
The difficult question is to know at what age such an intervention is beneficial, 
i.e. whether early treatment at a young age has an effect later on in life. 
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